{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:43:20Z","timestamp":1794285800743,"version":"4.9.0"},"reference-count":498,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA236585"],"award-info":[{"award-number":["P01CA236585"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA258125"],"award-info":[{"award-number":["R21CA258125"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA236585"],"award-info":[{"award-number":["P01CA236585"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA258125"],"award-info":[{"award-number":["R21CA258125"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI173050"],"award-info":[{"award-number":["R01AI173050"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI135201"],"award-info":[{"award-number":["R01AI135201"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ronald S. Hirshnerg Foundation Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease for which there is no effective treatment. A deep understanding of the mechanisms underlying the molecular pathogenesis, signaling pathways and risk factors leading to PDAC is of paramount importance for identifying novel targets, prognostic markers, preventive strategies, and signature markers for use in specific and personalized therapeutic procedures. Activating somatic mutations in the\n                    <jats:italic>KRAS<\/jats:italic>\n                    oncogene play a critical role in PDAC initiation and maintenance. Here, we highlight the complex interplay between KRAS signaling, the transcriptional coactivator YES1-associated protein (YAP) and Src family kinases (SFKs) in the pathogenesis of PDAC and drug sensitivity. We subsequently focused on diet-induced obesity, which has been correlated with an increased risk for developing PDAC in humans and mice and more severe clinical outcomes. Accumulating evidence also indicates that neural signals regulate critical functions of cancer cells, including their proliferation and dissemination, and that chronic stress promotes PDAC through the sympathetic nervous system via \u03b2-adrenergic receptors expressed by PDAC cells and other cells in the tumor microenvironment. Obesogenic mediators and stress neurotransmitters stimulate protein kinases, including PKA and PKD, which converge on CREB\/ATF1 phosphorylation in PDAC cells. Since stress and obesity cooperate to promote the progression of PDAC, novel combinatorial strategies to prevent this devastating disease could be developed, repositioning FDA-approved drugs that are extensively used to treat cardiovascular and metabolic disorders and diseases. Finally, we review new advances in the treatment of PDAC, focusing on the discovery of novel drugs that directly inhibit KRAS and YAP function.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02499-y","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:26:31Z","timestamp":1767425191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies"],"prefix":"10.1038","volume":"11","author":[{"given":"Enrique","family":"Rozengurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-4527","authenticated-orcid":false,"given":"Guido","family":"Eibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"2499_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld, C. et al. Neoadjuvant therapy for pancreatic cancer. Nat. Rev. Clin. Oncol. 20, 318\u2013337 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2499_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1053\/j.gastro.2024.05.028","volume":"167","author":"CS Leonhardt","year":"2024","unstructured":"Leonhardt, C. S. et al. Prognostic factors for early recurrence after resection of pancreatic cancer: a systematic review and meta-analysis. Gastroenterology 167, 977\u2013992 (2024).","journal-title":"Gastroenterology"},{"key":"2499_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1158\/2159-8290.CD-20-0359","volume":"10","author":"F Bednar","year":"2020","unstructured":"Bednar, F. & Pasca di Magliano, M. Chemotherapy and tumor evolution shape pancreatic cancer recurrence after resection. Cancer Discov. 10, 762\u2013764 (2020).","journal-title":"Cancer Discov."},{"key":"2499_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","volume":"25","author":"L Mastrantoni","year":"2024","unstructured":"Mastrantoni, L. et al. Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis. Lancet Oncol. 25, 1655\u20131665 (2024).","journal-title":"Lancet Oncol."},{"key":"2499_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41571-025-01019-9","volume":"22","author":"SB Dreyer","year":"2025","unstructured":"Dreyer, S. B., Beer, P., Hingorani, S. R. & Biankin, A. V. Improving outcomes of patients with pancreatic cancer. Nat. Rev. Clin. Oncol. 22, 439\u2013456 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2499_CR6","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"2499_CR7","first-page":"1509","volume":"35","author":"AJ Didier","year":"2024","unstructured":"Didier, A. J. et al. Trends in pancreatic cancer mortality in the United States 1999\u20132020: a CDC database population-based study. Cancer Causes Control 35, 1509\u20131516 (2024).","journal-title":"Cancer Causes Control"},{"key":"2499_CR8","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2021.18859","volume":"326","author":"S Gaddam","year":"2021","unstructured":"Gaddam, S. et al. Incidence of pancreatic cancer by age and sex in the US, 2000-2018. JAMA 326, 2075\u20132077 (2021).","journal-title":"JAMA"},{"key":"2499_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2023.01.022","volume":"164","author":"Y Abboud","year":"2023","unstructured":"Abboud, Y. et al. Increasing pancreatic cancer incidence in young women in the United States: a population-based time-trend analysis, 2001\u20132018. Gastroenterology 164, 978\u2013989.e976 (2023).","journal-title":"Gastroenterology"},{"key":"2499_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2018.10.029","volume":"156","author":"Y Omori","year":"2019","unstructured":"Omori, Y. et al. Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features. Gastroenterology 156, 647\u2013661.e642 (2019).","journal-title":"Gastroenterology"},{"key":"2499_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191937","volume":"135","author":"BA Pedro","year":"2025","unstructured":"Pedro, B. A. & Wood, L. D. Early neoplastic lesions of the pancreas: initiation, progression, and opportunities for precancer interception. J. Clin. Invest. 135, e191937 (2025).","journal-title":"J. Clin. Invest."},{"key":"2499_CR12","doi-asserted-by":"crossref","unstructured":"Pian, L. L. et al. Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges. Front. Endocrinol. (Lausanne) 15, 1401829 (2024).","DOI":"10.3389\/fendo.2024.1401829"},{"key":"2499_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 1039\u20131049 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2499_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel, E. M., Brand, R. E. & Goggins, M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164, 752\u2013765 (2023).","journal-title":"Gastroenterology"},{"key":"2499_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev-genet-120213-092228","volume":"49","author":"ML Leibowitz","year":"2015","unstructured":"Leibowitz, M. L., Zhang, C. Z. & Pellman, D. Chromothripsis: a new mechanism for rapid karyotype evolution. Annu. Rev. Genet. 49, 183\u2013211 (2015).","journal-title":"Annu. Rev. Genet."},{"key":"2499_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ccr.2013.04.025","volume":"23","author":"MM Shen","year":"2013","unstructured":"Shen, M. M. Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell 23, 567\u2013569 (2013).","journal-title":"Cancer Cell"},{"key":"2499_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378\u2013382 (2016).","journal-title":"Nature"},{"key":"2499_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","volume":"14","author":"J Tao","year":"2021","unstructured":"Tao, J. et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J. Hematol. Oncol. 14, 14 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2499_CR19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1053\/j.gastro.2016.03.040","volume":"150","author":"CC DuFort","year":"2016","unstructured":"DuFort, C. C., DelGiorno, K. E. & Hingorani, S. R. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology 150, 1545\u20131557.e1542 (2016).","journal-title":"Gastroenterology"},{"key":"2499_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02050-7","volume":"23","author":"Y Fu","year":"2024","unstructured":"Fu, Y. et al. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Mol. Cancer 23, 140 (2024).","journal-title":"Mol. Cancer"},{"key":"2499_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","volume":"178","author":"M Ligorio","year":"2019","unstructured":"Ligorio, M. et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178, 160\u2013175.e127 (2019).","journal-title":"Cell"},{"key":"2499_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","volume":"100","author":"E Hessmann","year":"2020","unstructured":"Hessmann, E. et al. Microenvironmental determinants of pancreatic cancer. Physiol. Rev. 100, 1707\u20131751 (2020).","journal-title":"Physiol. Rev."},{"key":"2499_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41590-025-02134-6","volume":"26","author":"M Shakiba","year":"2025","unstructured":"Shakiba, M. & Tuveson, D. A. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. Nat. Immunol. 26, 678\u2013691 (2025).","journal-title":"Nat. Immunol."},{"key":"2499_CR24","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/ijc.35326","volume":"156","author":"Y Liu","year":"2025","unstructured":"Liu, Y. & Xue, R. Pancreatic stellate cell: update on molecular investigations and clinical translation in pancreatic cancer. Int. J. Cancer 156, 1672\u20131685 (2025).","journal-title":"Int. J. Cancer"},{"key":"2499_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"2499_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Type I collagen deletion in \u03b1SMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 39, 548\u2013565.e546 (2021).","journal-title":"Cancer Cell"},{"key":"2499_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo, R., Xavier, C. P. R., Giovannetti, E. & Vasconcelos, M. H. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol. Med. 29, 439\u2013453 (2023).","journal-title":"Trends Mol. Med."},{"key":"2499_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54975-8","volume":"15","author":"L Veghini","year":"2024","unstructured":"Veghini, L. et al. Differential activity of MAPK signaling defines fibroblast subtypes in pancreatic cancer. Nat. Commun. 15, 10534 (2024).","journal-title":"Nat. Commun."},{"key":"2499_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025631118","volume":"118","author":"M Maddalena","year":"2021","unstructured":"Maddalena, M. et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc. Natl Acad. Sci. USA 118, e2025631118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10968-6","volume":"10","author":"C Vennin","year":"2019","unstructured":"Vennin, C. et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat. Commun. 10, 3637 (2019).","journal-title":"Nat. Commun."},{"key":"2499_CR31","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/0008-5472.CAN-24-2330","volume":"85","author":"EG Lloyd","year":"2025","unstructured":"Lloyd, E. G. et al. SMAD4 and KRAS status shape cancer cell-stromal crosstalk and therapeutic response in pancreatic cancer. Cancer Res. 85, 1368\u20131389 (2025).","journal-title":"Cancer Res."},{"key":"2499_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju, Y. et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis. Oncol. 8, 199 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"2499_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","volume":"25","author":"D Hanahan","year":"2025","unstructured":"Hanahan, D., Michielin, O. & Pittet, M. J. Convergent inducers and effectors of T-cell paralysis in the tumor microenvironment. Nat. Rev. Cancer 25, 41\u201358 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2017.10.007","volume":"54","author":"G Eibl","year":"2019","unstructured":"Eibl, G. & Rozengurt, E. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin. Cancer Biol. 54, 50\u201362 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"2499_CR35","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao, L. et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell 184, 5031\u20135052.e5026 (2021).","journal-title":"Cell"},{"key":"2499_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","volume":"18","author":"A Hayashi","year":"2021","unstructured":"Hayashi, A., Hong, J. & Iacobuzio-Donahue, C. A. The pancreatic cancer genome revisited. Nat. Rev. Gastroenterol. Hepatol. 18, 469\u2013481 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2499_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399\u2013405 (2012).","journal-title":"Nature"},{"key":"2499_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"CGAR Network","year":"2017","unstructured":"Network, C. G. A. R. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203.e113 (2017).","journal-title":"Cancer Cell"},{"key":"2499_CR39","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi, A. D. et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 156, 2242\u20132253.e2244 (2019).","journal-title":"Gastroenterology"},{"key":"2499_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","volume":"142","author":"M Kanda","year":"2012","unstructured":"Kanda, M. et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142, 730\u2013733.e739 (2012).","journal-title":"Gastroenterology"},{"key":"2499_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321\u2013337.e310 (2018).","journal-title":"Cell"},{"key":"2499_CR42","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs, G. A., Der, C. J. & Rossman, K. L. RAS isoforms and mutations in cancer at a glance. J. Cell Sci. 129, 1287\u20131292 (2016).","journal-title":"J. Cell Sci."},{"key":"2499_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17\u201333 (2017).","journal-title":"Cell"},{"key":"2499_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang, X. & Wu, H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J. Hematol. Oncol. 17, 108 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2499_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","volume":"39","author":"KL Bryant","year":"2014","unstructured":"Bryant, K. L., Mancias, J. D., Kimmelman, A. C. & Der, C. J. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 39, 91\u2013100 (2014).","journal-title":"Trends Biochem. Sci."},{"key":"2499_CR46","doi-asserted-by":"publisher","first-page":"e173420","DOI":"10.1001\/jamaoncol.2017.3420","volume":"4","author":"ZR Qian","year":"2018","unstructured":"Qian, Z. R. et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 4, e173420 (2018).","journal-title":"JAMA Oncol."},{"key":"2499_CR47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged?. Nat. Rev. Drug Discov. 19, 533\u2013552 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2499_CR48","doi-asserted-by":"publisher","first-page":"e2453588","DOI":"10.1001\/jamanetworkopen.2024.53588","volume":"8","author":"C Norton","year":"2025","unstructured":"Norton, C. et al. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw. Open 8, e2453588\u2013e2453588 (2025).","journal-title":"JAMA Netw. Open"},{"key":"2499_CR49","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/j.molcel.2024.06.027","volume":"84","author":"AM Mozzarelli","year":"2024","unstructured":"Mozzarelli, A. M., Simanshu, D. K. & Castel, P. Functional and structural insights into RAS effector proteins. Mol. Cell 84, 2807\u20132821 (2024).","journal-title":"Mol. Cell"},{"key":"2499_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2169-x","volume":"10","author":"F Dubois","year":"2019","unstructured":"Dubois, F., Bergot, E., Zalcman, G. & Levallet, G. RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review. Cell Death Dis. 10, 928 (2019).","journal-title":"Cell Death Dis."},{"key":"2499_CR51","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","volume":"18","author":"S Li","year":"2018","unstructured":"Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767\u2013777 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adt6552","volume":"18","author":"N Kabella","year":"2025","unstructured":"Kabella, N. et al. Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling. Sci. Signal 18, eadt6552 (2025).","journal-title":"Sci. Signal"},{"key":"2499_CR53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia, Z., Gavathiotis, E. & Poulikakos, P. I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 17, 676\u2013691 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01146-9","volume":"21","author":"L Rohrer","year":"2023","unstructured":"Rohrer, L. et al. Analysis of RAS and drug induced homo and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase. Cell Commun. Signal 21, 136 (2023).","journal-title":"Cell Commun. Signal"},{"key":"2499_CR55","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41594-024-01233-6","volume":"31","author":"P Maisonneuve","year":"2024","unstructured":"Maisonneuve, P. et al. The CNK-HYP scaffolding complex promotes RAF activation by enhancing KSR-MEK interaction. Nat. Struct. Mol. Biol. 31, 1028\u20131038 (2024).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2499_CR56","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/1873-3468.12740","volume":"591","author":"EB \u00dcnal","year":"2017","unstructured":"\u00dcnal, E. B., Uhlitz, F. & Bl\u00fcthgen, N. A compendium of ERK targets. FEBS Lett. 591, 2607\u20132615 (2017).","journal-title":"FEBS Lett."},{"key":"2499_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7685","volume":"6","author":"A Plotnikov","year":"2015","unstructured":"Plotnikov, A. et al. The nuclear translocation of ERK1\/2 as an anticancer target. Nat. Commun. 6, 6685 (2015).","journal-title":"Nat. Commun."},{"key":"2499_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102842","volume":"299","author":"WH Chang","year":"2023","unstructured":"Chang, W. H. et al. Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin. J. Biol. Chem. 299, 102842 (2023).","journal-title":"J. Biol. Chem."},{"key":"2499_CR59","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ccell.2018.10.001","volume":"34","author":"AV Vaseva","year":"2018","unstructured":"Vaseva, A. V. et al. KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism. Cancer Cell 34, 807\u2013822.e807 (2018).","journal-title":"Cancer Cell"},{"key":"2499_CR60","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/gutjnl-2016-312306","volume":"67","author":"VJ S\u00e1nchez-Ar\u00e9valo Lobo","year":"2018","unstructured":"S\u00e1nchez-Ar\u00e9valo Lobo, V. J. et al. c-Myc downregulation is required for preacinar to acinar maturation and pancreatic homeostasis. Gut 67, 707\u2013718 (2018).","journal-title":"Gut"},{"key":"2499_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","volume":"67","author":"IA Mayer","year":"2016","unstructured":"Mayer, I. A. & Arteaga, C. L. The PI3K\/AKT pathway as a target for cancer treatment. Annu. Rev. Med. 67, 11\u201328 (2016).","journal-title":"Annu. Rev. Med."},{"key":"2499_CR62","doi-asserted-by":"publisher","first-page":"a031450","DOI":"10.1101\/cshperspect.a031450","volume":"8","author":"AA Krygowska","year":"2018","unstructured":"Krygowska, A. A. & Castellano, E. PI3K: a crucial piece in the RAS signaling puzzle. Cold Spring Harb. Perspect. Med. 8, a031450 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2499_CR63","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1053\/j.gastro.2017.12.007","volume":"154","author":"JL Kopp","year":"2018","unstructured":"Kopp, J. L. et al. Loss of Pten and activation of Kras synergistically induce formation of intraductal papillary mucinous neoplasia from pancreatic ductal cells in mice. Gastroenterology 154, 1509\u20131523.e1505 (2018).","journal-title":"Gastroenterology"},{"key":"2499_CR64","doi-asserted-by":"crossref","unstructured":"Zhao, Y. et al. mTORC1 and mTORC2 converge on the Arp2\/3 complex to promote Kras(G12D)-induced acinar-to-ductal metaplasia and early pancreatic carcinogenesis. Gastroenterology 160, 1755\u20131770.e1717 (2021).","DOI":"10.1053\/j.gastro.2020.12.061"},{"key":"2499_CR65","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature25023","volume":"552","author":"H Yang","year":"2017","unstructured":"Yang, H. et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature 552, 368\u2013373 (2017).","journal-title":"Nature"},{"key":"2499_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119462","volume":"277","author":"J Tan","year":"2021","unstructured":"Tan, J. et al. Overexpressed RHEB promotes the progression of pancreatic adenocarcinoma. Life Sci. 277, 119462 (2021).","journal-title":"Life Sci."},{"key":"2499_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cellsig.2011.08.010","volume":"24","author":"H Wang","year":"2012","unstructured":"Wang, H. et al. Proline-rich Akt substrate of 40 kDa (PRAS40): a novel downstream target of PI3k\/Akt signaling pathway. Cell Signal 24, 17\u201324 (2012).","journal-title":"Cell Signal"},{"key":"2499_CR68","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.1158\/0008-5472.CAN-16-0810","volume":"76","author":"DR Driscoll","year":"2016","unstructured":"Driscoll, D. R. et al. mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Res. 76, 6911\u20136923 (2016).","journal-title":"Cancer Res."},{"key":"2499_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","volume":"21","author":"J Kim","year":"2019","unstructured":"Kim, J. & Guan, K. L. mTOR as a central hub of nutrient signaling and cell growth. Nat. Cell Biol. 21, 63\u201371 (2019).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu, G. Y. & Sabatini, D. M. mTOR at the nexus of nutrition, growth, aging and disease. Nat. Rev. Mol. Cell Biol. 21, 183\u2013203 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2499_CR71","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"2499_CR72","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.devcel.2022.02.024","volume":"57","author":"J Simcox","year":"2022","unstructured":"Simcox, J. & Lamming, D. W. The central moTOR of metabolism. Dev. Cell 57, 691\u2013706 (2022).","journal-title":"Dev. Cell"},{"key":"2499_CR73","doi-asserted-by":"publisher","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","volume":"8","author":"AM Waters","year":"2018","unstructured":"Waters, A. M. & Der, C. J. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb. Perspect. Med. 8, a031435 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2499_CR74","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1158\/2159-8290.CD-24-0614","volume":"15","author":"M Marasco","year":"2025","unstructured":"Marasco, M. et al. Direct inhibition of RAS reveals the features of oncogenic signaling driven by RAS G12 and Q61 mutations. Cancer Discov. 15, 1392\u20131409 (2025).","journal-title":"Cancer Discov."},{"key":"2499_CR75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.acr.2020.05.002","volume":"148","author":"JM Rhett","year":"2020","unstructured":"Rhett, J. M., Khan, I. & O\u2019Bryan, J. P. Biology, pathology, and therapeutic targeting of RAS. Adv. Cancer Res. 148, 69\u2013146 (2020).","journal-title":"Adv. Cancer Res."},{"key":"2499_CR76","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.1073\/pnas.1509123112","volume":"112","author":"X Nan","year":"2015","unstructured":"Nan, X. et al. Ras-GTP dimers activate the mitogen-activated protein kinase (MAPK) pathway. Proc. Natl Acad. Sci. USA 112, 7996\u20138001 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167392","volume":"434","author":"I Grozavu","year":"2022","unstructured":"Grozavu, I. et al. D154Q mutation does not alter KRAS dimerization. J. Mol. Biol. 434, 167392 (2022).","journal-title":"J. Mol. Biol."},{"key":"2499_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102661","volume":"298","author":"M Whaby","year":"2022","unstructured":"Whaby, M. et al. Mutations in the \u03b14-\u03b15 allosteric lobe of RAS do not significantly impair RAS signaling or self-association. J. Biol. Chem. 298, 102661 (2022).","journal-title":"J. Biol. Chem."},{"key":"2499_CR79","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.molcel.2023.03.008","volume":"83","author":"DK Simanshu","year":"2023","unstructured":"Simanshu, D. K., Philips, M. R. & Hancock, J. F. Consensus on the RAS dimerization hypothesis: strong evidence for lipid-mediated clustering but not for G-domain-mediated interactions. Mol. Cell 83, 1210\u20131215 (2023).","journal-title":"Mol. Cell"},{"key":"2499_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107859","volume":"300","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. Experimental variables determine the outcome of RAS-RAS interactions. J. Biol. Chem. 300, 107859 (2024).","journal-title":"J. Biol. Chem."},{"key":"2499_CR81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405986121","volume":"121","author":"SD Yun","year":"2024","unstructured":"Yun, S. D. et al. Capturing RAS oligomerization on a membrane. Proc. Natl Acad. Sci. USA 121, e2405986121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR82","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1091\/mbc.E18-10-0676","volume":"30","author":"FE Hood","year":"2019","unstructured":"Hood, F. E. et al. Isoform-specific Ras signaling is growth factor dependent. Mol. Biol. Cell 30, 1108\u20131117 (2019).","journal-title":"Mol. Biol. Cell"},{"key":"2499_CR83","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1158\/0008-5472.CAN-24-4576","volume":"85","author":"C Tonelli","year":"2025","unstructured":"Tonelli, C. et al. FGFR2 abrogation intercepts pancreatic ductal adenocarcinoma development. Cancer Res. 85, 1960\u20131977 (2025).","journal-title":"Cancer Res."},{"key":"2499_CR84","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2012.07.024","volume":"22","author":"CM Ardito","year":"2012","unstructured":"Ardito, C. M. et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22, 304\u2013317 (2012).","journal-title":"Cancer Cell"},{"key":"2499_CR85","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccr.2012.08.001","volume":"22","author":"C Navas","year":"2012","unstructured":"Navas, C. et al. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318\u2013330 (2012).","journal-title":"Cancer Cell"},{"key":"2499_CR86","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1053\/j.gastro.2018.12.039","volume":"156","author":"LD Wood","year":"2019","unstructured":"Wood, L. D., Yurgelun, M. B. & Goggins, M. G. Genetics of familial and sporadic pancreatic cancer. Gastroenterology 156, 2041\u20132055 (2019).","journal-title":"Gastroenterology"},{"key":"2499_CR87","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1038\/onc.2015.441","volume":"35","author":"JM Bailey","year":"2016","unstructured":"Bailey, J. M. et al. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene 35, 4282\u20134288 (2016).","journal-title":"Oncogene"},{"key":"2499_CR88","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-018-0481-8","volume":"561","author":"AP Makohon-Moore","year":"2018","unstructured":"Makohon-Moore, A. P. et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561, 201\u2013205 (2018).","journal-title":"Nature"},{"key":"2499_CR89","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/2159-8290.CD-20-1228","volume":"11","author":"MP Kim","year":"2021","unstructured":"Kim, M. P. et al. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov. 11, 2094\u20132111 (2021).","journal-title":"Cancer Discov."},{"key":"2499_CR90","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1158\/1078-0432.CCR-22-3930","volume":"29","author":"H Singh","year":"2023","unstructured":"Singh, H. et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer. Clin. Cancer Res. 29, 4627\u20134643 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR91","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","volume":"6","author":"NJ Roberts","year":"2016","unstructured":"Roberts, N. J. et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 6, 166\u2013175 (2016).","journal-title":"Cancer Discov."},{"key":"2499_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35666","volume":"131","author":"BW Katona","year":"2025","unstructured":"Katona, B. W. et al. The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation. Cancer 131, e35666 (2025).","journal-title":"Cancer"},{"key":"2499_CR93","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.gastro.2017.10.015","volume":"154","author":"RC Grant","year":"2018","unstructured":"Grant, R. C. et al. Exome-wide association study of pancreatic cancer risk. Gastroenterology 154, 719\u2013722.e713 (2018).","journal-title":"Gastroenterology"},{"key":"2499_CR94","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1001\/jama.2009.1529","volume":"302","author":"F Kastrinos","year":"2009","unstructured":"Kastrinos, F. et al. Risk of pancreatic cancer in families with Lynch syndrome. J. Am. Med. Assoc. 302, 1790\u20131795 (2009).","journal-title":"J. Am. Med. Assoc."},{"key":"2499_CR95","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-11-0194","volume":"2","author":"NJ Roberts","year":"2012","unstructured":"Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2, 41\u201346 (2012).","journal-title":"Cancer Discov."},{"key":"2499_CR96","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/01.MP.0000075645.97329.86","volume":"16","author":"F Sahin","year":"2003","unstructured":"Sahin, F. et al. Loss of Stk11\/Lkb1 expression in pancreatic and biliary neoplasms. Mod. Pathol. 16, 686\u2013691 (2003).","journal-title":"Mod. Pathol."},{"key":"2499_CR97","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1158\/0008-5472.CAN-12-4384","volume":"73","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 73, 4909\u20134922 (2013).","journal-title":"Cancer Res."},{"key":"2499_CR98","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1158\/0008-5472.CAN-13-0566","volume":"73","author":"A Criscimanna","year":"2013","unstructured":"Criscimanna, A. et al. PanIN-specific regulation of Wnt signaling by HIF2\u03b1 during early pancreatic tumorigenesis. Cancer Res. 73, 4781\u20134790 (2013).","journal-title":"Cancer Res."},{"key":"2499_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0689-5","volume":"16","author":"Q Zhang","year":"2017","unstructured":"Zhang, Q. et al. Hypoxia-inducible factor-2\u03b1 promotes tumor progression and has crosstalk with Wnt\/\u03b2-catenin signaling in pancreatic cancer. Mol. Cancer 16, 119 (2017).","journal-title":"Mol. Cancer"},{"key":"2499_CR100","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","volume":"4","author":"SR Hingorani","year":"2003","unstructured":"Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437\u2013450 (2003).","journal-title":"Cancer Cell"},{"key":"2499_CR101","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"2499_CR102","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.275776.115","volume":"30","author":"H Ying","year":"2016","unstructured":"Ying, H. et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 30, 355\u2013385 (2016).","journal-title":"Genes Dev."},{"key":"2499_CR103","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/PPO.0b013e31827ab4c4","volume":"18","author":"CB Westphalen","year":"2012","unstructured":"Westphalen, C. B. & Olive, K. P. Genetically engineered mouse models of pancreatic cancer. Cancer J. 18, 502\u2013510 (2012).","journal-title":"Cancer J."},{"key":"2499_CR104","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.05.011","volume":"19","author":"C Guerra","year":"2011","unstructured":"Guerra, C. et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19, 728\u2013739 (2011).","journal-title":"Cancer Cell"},{"key":"2499_CR105","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1111\/cas.16183","volume":"115","author":"H Maeda","year":"2024","unstructured":"Maeda, H. & Kakiuchi, N. Clonal expansion in normal tissues. Cancer Sci. 115, 2117\u20132124 (2024).","journal-title":"Cancer Sci."},{"key":"2499_CR106","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI59227","volume":"122","author":"MA Collins","year":"2012","unstructured":"Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639\u2013653 (2012).","journal-title":"J. Clin. Invest."},{"key":"2499_CR107","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1101\/gad.1158703","volume":"17","author":"AJ Aguirre","year":"2003","unstructured":"Aguirre, A. J. et al. Activated Kras and Ink4a\/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112\u20133126 (2003).","journal-title":"Genes Dev."},{"key":"2499_CR108","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1101\/gad.1478706","volume":"20","author":"N Bardeesy","year":"2006","unstructured":"Bardeesy, N. et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 20, 3130\u20133146 (2006).","journal-title":"Genes Dev."},{"key":"2499_CR109","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese, A. M. et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat. Med. 31, 466\u2013477 (2025).","journal-title":"Nat. Med."},{"key":"2499_CR110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature25459","volume":"554","author":"S Mueller","year":"2018","unstructured":"Mueller, S. et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554, 62\u201368 (2018).","journal-title":"Nature"},{"key":"2499_CR111","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semcdb.2016.07.012","volume":"58","author":"B Zhou","year":"2016","unstructured":"Zhou, B., Der, C. J. & Cox, A. D. The role of wild type RAS isoforms in cancer. Semin Cell Dev. Biol. 58, 60\u201369 (2016).","journal-title":"Semin Cell Dev. Biol."},{"key":"2499_CR112","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1158\/0008-5472.CAN-23-2709","volume":"85","author":"SK Fey","year":"2025","unstructured":"Fey, S. K. et al. KRAS loss of heterozygosity promotes MAPK-dependent pancreatic ductal adenocarcinoma initiation and induces therapeutic sensitivity to MEK inhibition. Cancer Res. 85, 251\u2013262 (2025).","journal-title":"Cancer Res."},{"key":"2499_CR113","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cell.2017.12.020","volume":"172","author":"C Ambrogio","year":"2018","unstructured":"Ambrogio, C. et al. KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS. Cell 172, 857\u2013868.e815 (2018).","journal-title":"Cell"},{"key":"2499_CR114","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41388-021-02040-9","volume":"40","author":"H Yan","year":"2021","unstructured":"Yan, H. et al. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene 40, 6759\u20136771 (2021).","journal-title":"Oncogene"},{"key":"2499_CR115","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324\u2013338 (2015).","journal-title":"Cell"},{"key":"2499_CR116","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ijc.35443","volume":"157","author":"C Nitschke","year":"2025","unstructured":"Nitschke, C. et al. Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma. Int J. Cancer 157, 760\u2013772 (2025).","journal-title":"Int J. Cancer"},{"key":"2499_CR117","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1053\/j.gastro.2024.06.008","volume":"167","author":"\u00c1 Fern\u00e1ndez","year":"2024","unstructured":"Fern\u00e1ndez, \u00c1 et al. A single-cell atlas of the murine pancreatic ductal tree identifies novel cell populations with potential implications in pancreas regeneration and exocrine pathogenesis. Gastroenterology 167, 944\u2013960.e915 (2024).","journal-title":"Gastroenterology"},{"key":"2499_CR118","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191945","volume":"135","author":"V Pantazopoulou","year":"2025","unstructured":"Pantazopoulou, V. et al. Experimental models of pancreas cancer: what has been the impact for precision medicine?. J. Clin. Invest. 135, e191945 (2025).","journal-title":"J. Clin. Invest."},{"key":"2499_CR119","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500\u2013503 (2011).","journal-title":"Nat. Med."},{"key":"2499_CR120","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"2499_CR121","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"2499_CR122","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael, B. J. et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203.e113 (2017).","journal-title":"Cancer Cell"},{"key":"2499_CR123","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson, E. A., Bailey, P., Chang, D. K. & Biankin, A. V. Molecular subtypes of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 207\u2013220 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2499_CR124","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","volume":"22","author":"AA Connor","year":"2022","unstructured":"Connor, A. A. & Gallinger, S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat. Rev. Cancer 22, 131\u2013142 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR125","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","volume":"8","author":"AJ Aguirre","year":"2018","unstructured":"Aguirre, A. J. et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 8, 1096\u20131111 (2018).","journal-title":"Cancer Discov."},{"key":"2499_CR126","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR127","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/annonc\/mdz181","volume":"30","author":"S Martens","year":"2019","unstructured":"Martens, S. et al. Different shades of pancreatic ductal adenocarcinoma, different paths toward precision therapeutic applications. Ann. Oncol. 30, 1428\u20131436 (2019).","journal-title":"Ann. Oncol."},{"key":"2499_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113434","volume":"42","author":"Y Ohara","year":"2023","unstructured":"Ohara, Y. et al. SERPINB3-MYC axis induces the basal-like\/squamous subtype and enhances disease progression in pancreatic cancer. Cell Rep. 42, 113434 (2023).","journal-title":"Cell Rep."},{"key":"2499_CR129","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane, G. M. et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 26, 4901\u20134910 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR130","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/gutjnl-2015-311256","volume":"66","author":"P Martinelli","year":"2017","unstructured":"Martinelli, P. et al. GATA6 regulates EMT and tumor dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut 66, 1665\u20131676 (2017).","journal-title":"Gut"},{"key":"2499_CR131","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","volume":"83","author":"HL Williams","year":"2023","unstructured":"Williams, H. L. et al. Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals coexpressor phenotypes and extensive intratumoral heterogeneity. Cancer Res. 83, 441\u2013455 (2023).","journal-title":"Cancer Res."},{"key":"2499_CR132","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156305","volume":"132","author":"Z Zhong","year":"2022","unstructured":"Zhong, Z., Harmston, N., Wood, K. C., Madan, B. & Virshup, D. M. A p300\/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models. J. Clin. Invest. 132, e156305 (2022).","journal-title":"J. Clin. Invest."},{"key":"2499_CR133","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.celrep.2018.10.051","volume":"25","author":"TDD Somerville","year":"2018","unstructured":"Somerville, T. D. D. et al. TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma. Cell Rep. 25, 1741\u20131755.e1747 (2018).","journal-title":"Cell Rep."},{"key":"2499_CR134","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1158\/1078-0432.CCR-24-2200","volume":"31","author":"N Yamamoto","year":"2025","unstructured":"Yamamoto, N. et al. HMGA2 expression predicts subtype, survival, and treatment outcome in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 31, 733\u2013745 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR135","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231\u2013240 (2020).","journal-title":"Nat. Genet."},{"key":"2499_CR136","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1158\/1078-0432.CCR-20-1039","volume":"27","author":"DJ Birnbaum","year":"2021","unstructured":"Birnbaum, D. J. et al. Transcriptomic analysis of laser capture microdissected tumors reveals cancer- and stromal-specific molecular subtypes of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 27, 2314\u20132325 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR137","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.trecan.2022.08.005","volume":"8","author":"E Espinet","year":"2022","unstructured":"Espinet, E., Klein, L., Pur\u00e9, E. & Singh, S. K. Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer 8, 1060\u20131071 (2022).","journal-title":"Trends Cancer"},{"key":"2499_CR138","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/gutjnl-2023-329807","volume":"73","author":"F Lupo","year":"2024","unstructured":"Lupo, F. et al. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Gut 73, 1321\u20131335 (2024).","journal-title":"Gut"},{"key":"2499_CR139","doi-asserted-by":"publisher","first-page":"12214","DOI":"10.1096\/fj.202000363RR","volume":"34","author":"N Juiz","year":"2020","unstructured":"Juiz, N. et al. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype. FASEB J. 34, 12214\u201312228 (2020).","journal-title":"FASEB J."},{"key":"2499_CR140","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107206","volume":"40","author":"M Milan","year":"2021","unstructured":"Milan, M., Diaferia, G. R. & Natoli, G. Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants. EMBO J. 40, e10720 (2021).","journal-title":"EMBO J."},{"key":"2499_CR141","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43018-019-0010-1","volume":"1","author":"A Hayashi","year":"2020","unstructured":"Hayashi, A. et al. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat. Cancer 1, 59\u201374 (2020).","journal-title":"Nat. Cancer"},{"key":"2499_CR142","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1158\/1078-0432.CCR-24-2183","volume":"31","author":"IM Loveless","year":"2025","unstructured":"Loveless, I. M. et al. Human pancreatic cancer single-cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells. Clin. Cancer Res. 31, 756\u2013772 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02003-0","volume":"23","author":"JK Park","year":"2024","unstructured":"Park, J. K. et al. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications. Mol. Cancer 23, 87 (2024).","journal-title":"Mol. Cancer"},{"key":"2499_CR144","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/2159-8290.CD-20-0633","volume":"11","author":"BM Flowers","year":"2021","unstructured":"Flowers, B. M. et al. Cell of origin influences pancreatic cancer subtype. Cancer Discov. 11, 660\u2013677 (2021).","journal-title":"Cancer Discov."},{"key":"2499_CR145","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-20-0133","volume":"10","author":"K Miyabayashi","year":"2020","unstructured":"Miyabayashi, K. et al. Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer Discov. 10, 1566\u20131589 (2020).","journal-title":"Cancer Discov."},{"key":"2499_CR146","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh, A. et al. A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489\u2013500 (2009).","journal-title":"Cancer Cell"},{"key":"2499_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00942-5","volume":"8","author":"MD Muzumdar","year":"2017","unstructured":"Muzumdar, M. D. et al. Survival of pancreatic cancer cells lacking KRAS function. Nat. Commun. 8, 1090 (2017).","journal-title":"Nat. Commun."},{"key":"2499_CR148","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130811","volume":"4","author":"B Tu","year":"2019","unstructured":"Tu, B. et al. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI insight 4, e130811 (2019).","journal-title":"JCI insight"},{"key":"2499_CR149","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656\u2013670 (2012).","journal-title":"Cell"},{"key":"2499_CR150","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor, A. et al. Yap1 activation enables bypass of oncogenic KRAS addiction in pancreatic cancer. Cell 158, 185\u2013197 (2014).","journal-title":"Cell"},{"key":"2499_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu, C. et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol. Cancer 21, 159 (2022).","journal-title":"Mol. Cancer"},{"key":"2499_CR152","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1158\/2159-8290.CD-19-0597","volume":"10","author":"P Hou","year":"2020","unstructured":"Hou, P. et al. Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. Cancer Discov. 10, 1058\u20131077 (2020).","journal-title":"Cancer Discov."},{"key":"2499_CR153","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-021-00375-9","volume":"21","author":"SA Kerk","year":"2021","unstructured":"Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M. & Lyssiotis, C. A. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat. Rev. Cancer 21, 510\u2013525 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gad.274027.115","volume":"30","author":"Z Meng","year":"2016","unstructured":"Meng, Z., Moroishi, T. & Guan, K.-L. Mechanisms of Hippo pathway regulation. Genes Dev. 30, 1\u201317 (2016).","journal-title":"Genes Dev."},{"key":"2499_CR155","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.tcb.2015.11.004","volume":"26","author":"G Santinon","year":"2016","unstructured":"Santinon, G., Pocaterra, A. & Dupont, S. Control of YAP\/TAZ activity by metabolic and nutrient-sensing pathways. Trends Cell Biol. 26, 289\u2013299 (2016).","journal-title":"Trends Cell Biol."},{"key":"2499_CR156","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41568-019-0168-y","volume":"19","author":"F Zanconato","year":"2019","unstructured":"Zanconato, F., Cordenonsi, M. & Piccolo, S. Y. A. P. TAZ: a signalling hub of the tumour microenvironment. Nat. Rev. Cancer 19, 454\u2013464 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10729-5","volume":"10","author":"J Park","year":"2019","unstructured":"Park, J. et al. Switch-like enhancement of epithelial\u2013mesenchymal transition by YAP through feedback regulation of WT1 and Rho-family GTPases. Nat. Commun. 10, 2797 (2019).","journal-title":"Nat. Commun."},{"key":"2499_CR158","doi-asserted-by":"publisher","first-page":"113926","DOI":"10.1016\/j.celrep.2024.113926","volume":"43","author":"Z Zhong","year":"2024","unstructured":"Zhong, Z., Jiao, Z. & Yu, F. X. The Hippo signaling pathway in development and regeneration. Cell Rep. 43, 113926 (2024).","journal-title":"Cell Rep."},{"key":"2499_CR159","first-page":"9","volume":"4","author":"S Piccolo","year":"2023","unstructured":"Piccolo, S., Panciera, T., Contessotto, P. & Cordenonsi, M. YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat. Cancer 4, 9\u201326 (2023).","journal-title":"Nat. Cancer"},{"key":"2499_CR160","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.devcel.2015.08.014","volume":"34","author":"Y Zheng","year":"2015","unstructured":"Zheng, Y. et al. Identification of happyhour\/MAP4K as alternative Hpo\/Mst-like kinases in the Hippo kinase cascade. Dev. Cell 34, 642\u2013655 (2015).","journal-title":"Dev. Cell"},{"key":"2499_CR161","doi-asserted-by":"publisher","first-page":"8357","DOI":"10.1038\/ncomms9357","volume":"6","author":"Z Meng","year":"2015","unstructured":"Meng, Z. et al. MAP4K family kinases act in parallel to MST1\/2 to activate LATS1\/2 in the Hippo pathway. Nat. Commun. 6, 8357\u20138357 (2015).","journal-title":"Nat. Commun."},{"key":"2499_CR162","doi-asserted-by":"publisher","first-page":"18230","DOI":"10.1074\/jbc.RA118.004187","volume":"293","author":"S Mana-Capelli","year":"2018","unstructured":"Mana-Capelli, S. & McCollum, D. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling. J. Biol. Chem. 293, 18230\u201318241 (2018).","journal-title":"J. Biol. Chem."},{"key":"2499_CR163","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.molcel.2022.03.027","volume":"82","author":"S Qi","year":"2022","unstructured":"Qi, S. et al. WWC proteins mediate LATS1\/2 activation by Hippo kinases and imply a tumor suppression strategy. Mol. Cell 82, 1850\u20131864.e1857 (2022).","journal-title":"Mol. Cell"},{"key":"2499_CR164","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1074\/jbc.RA118.002715","volume":"293","author":"SW Plouffe","year":"2018","unstructured":"Plouffe, S. W. et al. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J. Biol. Chem. 293, 11230\u201311240 (2018).","journal-title":"J. Biol. Chem."},{"key":"2499_CR165","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15252\/embr.201642683","volume":"18","author":"S Moon","year":"2017","unstructured":"Moon, S. et al. Phosphorylation by NLK inhibits YAP-14-3-3-interactions and induces its nuclear localization. EMBO Rep. 18, 61\u201371 (2017).","journal-title":"EMBO Rep."},{"key":"2499_CR166","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro, A., Panciera, T. & Piccolo, S. YAP\/TAZ upstream signals and downstream responses. Nat. Cell Biol. 20, 888\u2013899 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR167","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi, T., Hansen, C. G. & Guan, K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73\u201379 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR168","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1242\/dev.102376","volume":"141","author":"X Varelas","year":"2014","unstructured":"Varelas, X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141, 1614\u20131626 (2014).","journal-title":"Development"},{"key":"2499_CR169","doi-asserted-by":"publisher","first-page":"27928","DOI":"10.1074\/jbc.M115.692285","volume":"290","author":"ML Finch-Edmondson","year":"2015","unstructured":"Finch-Edmondson, M. L. et al. TAZ protein accumulation is negatively regulated by YAP abundance in mammalian cells. J. Biol. Chem. 290, 27928\u201327938 (2015).","journal-title":"J. Biol. Chem."},{"key":"2499_CR170","doi-asserted-by":"publisher","first-page":"658481","DOI":"10.3389\/fcell.2021.658481","volume":"9","author":"YS Cho","year":"2021","unstructured":"Cho, Y. S. & Jiang, J. Hippo-Independent Regulation of Yki\/Yap\/Taz: a non-canonical view. Front. Cell Dev. Biol. 9, 658481 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2499_CR171","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ncb3111","volume":"17","author":"J-S Mo","year":"2015","unstructured":"Mo, J.-S. et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol. 17, 500\u2013510 (2015).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR172","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ncb3113","volume":"17","author":"W Wang","year":"2015","unstructured":"Wang, W. et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol. 17, 490\u2013499 (2015).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR173","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1158\/0008-5472.CAN-13-2049","volume":"73","author":"S Yang","year":"2013","unstructured":"Yang, S. et al. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. 73, 6722\u20136733 (2013).","journal-title":"Cancer Res."},{"key":"2499_CR174","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1101\/gad.333146.119","volume":"34","author":"YS Cho","year":"2020","unstructured":"Cho, Y. S. et al. CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki\/Yap\/Taz in the nucleus. Genes Dev. 34, 53\u201371 (2020).","journal-title":"Genes Dev."},{"key":"2499_CR175","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1158\/0008-5472.CAN-19-1339","volume":"79","author":"J Seo","year":"2019","unstructured":"Seo, J. et al. MK5 regulates YAP stability and is a molecular target in YAP-driven cancers. Cancer Res. 79, 6139\u20136152 (2019).","journal-title":"Cancer Res."},{"key":"2499_CR176","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191817","volume":"217","author":"L An","year":"2020","unstructured":"An, L. et al. MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non-canonical pathway. J. Exp. Med. 217, e20191817 (2020).","journal-title":"J. Exp. Med."},{"key":"2499_CR177","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.jbc.2024.107709","volume":"300","author":"D Zhang","year":"2024","unstructured":"Zhang, D., Qi, Y., Inuzuka, H., Liu, J. & Wei, W. O-GlcNAcylation in tumorigenesis and its implications for cancer therapy. J. Biol. Chem. 300, 107709 (2024).","journal-title":"J. Biol. Chem."},{"key":"2499_CR178","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1053\/j.gastro.2025.01.240","volume":"168","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. The moonlighting function of glutaminase 2 promotes immune evasion of pancreatic ductal adenocarcinoma by tubulin tyrosine ligase-like 1-mediated Yes1 associated transcriptional regulator glutamylation. Gastroenterology 168, 1137\u20131152 (2025).","journal-title":"Gastroenterology"},{"key":"2499_CR179","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/MPA.0000000000000867","volume":"46","author":"MT Salcedo Allende","year":"2017","unstructured":"Salcedo Allende, M. T. et al. Overexpression of Yes associated protein 1, an independent prognostic marker in patients with pancreatic ductal adenocarcinoma, correlated with liver metastasis and poor prognosis. Pancreas 46, 913\u2013920 (2017).","journal-title":"Pancreas"},{"key":"2499_CR180","doi-asserted-by":"publisher","first-page":"ra42","DOI":"10.1126\/scisignal.2005049","volume":"7","author":"W Zhang","year":"2014","unstructured":"Zhang, W. et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 7, ra42 (2014).","journal-title":"Sci. Signal."},{"key":"2499_CR181","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1053\/j.gastro.2016.05.006","volume":"151","author":"R Gruber","year":"2016","unstructured":"Gruber, R. et al. YAP1 and TAZ control pancreatic cancer initiation in mice by direct up-regulation of JAK\u2013STAT3 signaling. Gastroenterology 151, 526\u2013539 (2016).","journal-title":"Gastroenterology"},{"key":"2499_CR182","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143414","volume":"131","author":"T Tamura","year":"2021","unstructured":"Tamura, T. et al. Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation. J. Clin. Invest. 131, e143414 (2021).","journal-title":"J. Clin. Invest."},{"key":"2499_CR183","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.devcel.2019.07.022","volume":"51","author":"S Murakami","year":"2019","unstructured":"Murakami, S. et al. A Yap-Myc-Sox2-p53 regulatory network dictates metabolic homeostasis and differentiation in Kras-driven pancreatic ductal adenocarcinomas. Dev. Cell 51, 113\u2013128.e119 (2019).","journal-title":"Dev. Cell"},{"key":"2499_CR184","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/onc.2016.288","volume":"36","author":"S Murakami","year":"2017","unstructured":"Murakami, S. et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene 36, 1232\u20131244 (2017).","journal-title":"Oncogene"},{"key":"2499_CR185","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250\u2013256 (2015).","journal-title":"Nat. Genet."},{"key":"2499_CR186","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","volume":"158","author":"DD Shao","year":"2014","unstructured":"Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171\u2013184 (2014).","journal-title":"Cell"},{"key":"2499_CR187","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1101\/gad.340661.120","volume":"34","author":"B King","year":"2020","unstructured":"King, B., Araki, J., Palm, W. & Thompson, C. B. Yap\/Taz promote the scavenging of extracellular nutrients through macropinocytosis. Genes Dev. 34, 1345\u20131358 (2020).","journal-title":"Genes Dev."},{"key":"2499_CR188","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","volume":"162","author":"HW Park","year":"2015","unstructured":"Park, H. W. et al. Alternative Wnt signaling activates YAP\/TAZ. Cell 162, 780\u2013794 (2015).","journal-title":"Cell"},{"key":"2499_CR189","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1053\/j.gastro.2020.12.077","volume":"160","author":"M Liu","year":"2021","unstructured":"Liu, M. et al. Zinc-dependent regulation of ZEB1 and YAP1 coactivation promotes epithelial\u2013mesenchymal transition plasticity and metastasis in pancreatic cancer. Gastroenterology 160, 1771\u20131783.e1 (2021).","journal-title":"Gastroenterology"},{"key":"2499_CR190","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/ncb3513","volume":"19","author":"AM Krebs","year":"2017","unstructured":"Krebs, A. M. et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518\u2013529 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR191","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-018-0658-1","volume":"563","author":"L Chang","year":"2018","unstructured":"Chang, L. et al. The SWI\/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature 563, 265\u2013269 (2018).","journal-title":"Nature"},{"key":"2499_CR192","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1158\/0008-5472.CAN-20-0907","volume":"80","author":"J Park","year":"2020","unstructured":"Park, J. et al. YAP and AP-1 cooperate to initiate pancreatic cancer development from ductal cells in mice. Cancer Res 80, 4768\u20134779 (2020).","journal-title":"Cancer Res"},{"key":"2499_CR193","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.331546.119","volume":"34","author":"JH Koo","year":"2020","unstructured":"Koo, J. H. et al. Induction of AP-1 by YAP\/TAZ contributes to cell proliferation and organ growth. Genes Dev. 34, 72\u201386 (2020).","journal-title":"Genes Dev."},{"key":"2499_CR194","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fcell.2019.00159","volume":"7","author":"N Raj","year":"2019","unstructured":"Raj, N. & Bam, R. Reciprocal crosstalk between YAP1\/Hippo pathway and the p53 family proteins: mechanisms and outcomes in cancer. Front. Cell Dev. Biol. 7, 159\u2013159 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"2499_CR195","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1158\/0008-5472.CAN-09-0418","volume":"69","author":"K Kisfalvi","year":"2009","unstructured":"Kisfalvi, K., Eibl, G., Sinnett-Smith, J. & Rozengurt, E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 69, 6539\u20136545 (2009).","journal-title":"Cancer Res."},{"key":"2499_CR196","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-09-2229","volume":"16","author":"E Rozengurt","year":"2010","unstructured":"Rozengurt, E., Sinnett-Smith, J. & Kisfalvi, K. Crosstalk between Insulin\/Insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 16, 2505\u20132511 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR197","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/1541-7786.MCR-17-0023","volume":"15","author":"F Hao","year":"2017","unstructured":"Hao, F. et al. Insulin receptor and GPCR crosstalk stimulates YAP via PI3K and PKD in pancreatic cancer cells. Mol. Cancer Res. 15, 929\u2013941 (2017).","journal-title":"Mol. Cancer Res."},{"key":"2499_CR198","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.tibs.2020.01.005","volume":"45","author":"A Ardestani","year":"2020","unstructured":"Ardestani, A. & Maedler, K. STRIPAK is a regulatory hub initiating Hippo signaling. Trends Biochem. Sci. 45, 280\u2013283 (2020).","journal-title":"Trends Biochem. Sci."},{"key":"2499_CR199","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-09-1834","volume":"16","author":"EL Mayer","year":"2010","unstructured":"Mayer, E. L. & Krop, I. E. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin. Cancer Res. 16, 3526\u20133532 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00750-x","volume":"19","author":"MA Ortiz","year":"2021","unstructured":"Ortiz, M. A. et al. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Commun. Signal 19, 67 (2021).","journal-title":"Cell Commun. Signal"},{"key":"2499_CR201","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41556-020-0560-6","volume":"22","author":"L Moro","year":"2020","unstructured":"Moro, L. et al. Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Nat. Cell Biol. 22, 1130\u20131142 (2020).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR202","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1158\/1535-7163.MCT-09-1212","volume":"9","author":"NS Nagaraj","year":"2010","unstructured":"Nagaraj, N. S., Smith, J. J., Revetta, F., Washington, M. K. & Merchant, N. B. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol. Cancer Ther. 9, 2322\u20132332 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR203","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/MPA.0000000000000103","volume":"43","author":"DW Je","year":"2014","unstructured":"Je, D. W. et al. The inhibition of Src family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas 43, 768\u2013776 (2014).","journal-title":"Pancreas"},{"key":"2499_CR204","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1158\/1535-7163.MCT-21-0964","volume":"21","author":"J Sinnett-Smith","year":"2022","unstructured":"Sinnett-Smith, J. et al. Opposite effects of Src family kinases on YAP and ERK activation in pancreatic cancer cells: implications for targeted therapy. Mol. Cancer Ther. 21, 1652\u20131662 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR205","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/1535-7163.MCT-21-0958","volume":"21","author":"I Garmendia","year":"2022","unstructured":"Garmendia, I., Redin, E., Montuenga, L. M. & Calvo, A. YES1: a novel therapeutic target and biomarker in cancer. Mol. Cancer Ther. 21, 1371\u20131380 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR206","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/j.gastro.2010.03.034","volume":"139","author":"JP Morton","year":"2010","unstructured":"Morton, J. P. et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139, 292\u2013303 (2010).","journal-title":"Gastroenterology"},{"key":"2499_CR207","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/onc.2010.589","volume":"30","author":"DJ Shields","year":"2011","unstructured":"Shields, D. J. et al. Oncogenic Ras\/Src cooperativity in pancreatic neoplasia. Oncogene 30, 2123\u20132134 (2011).","journal-title":"Oncogene"},{"key":"2499_CR208","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1158\/0008-5472.CAN-17-0391","volume":"77","author":"Y Si","year":"2017","unstructured":"Si, Y. et al. Src inhibits the Hippo tumor suppressor pathway through tyrosine phosphorylation of Lats1. Cancer Res. 77, 4868\u20134880 (2017).","journal-title":"Cancer Res."},{"key":"2499_CR209","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1074\/jbc.RA118.004364","volume":"294","author":"JM Lamar","year":"2019","unstructured":"Lamar, J. M. et al. SRC tyrosine kinase activates the YAP\/TAZ axis and thereby drives tumor growth and metastasis. J. Biol. Chem. 294, 2302\u20132317 (2019).","journal-title":"J. Biol. Chem."},{"key":"2499_CR210","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi, K. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519, 57\u201362 (2015).","journal-title":"Nature"},{"key":"2499_CR211","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.cell.2012.11.026","volume":"151","author":"J Rosenbluh","year":"2012","unstructured":"Rosenbluh, J. et al. \u03b2-catenin driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457\u20131473 (2012).","journal-title":"Cell"},{"key":"2499_CR212","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1101\/gad.274951.115","volume":"30","author":"P Li","year":"2016","unstructured":"Li, P. et al. \u03b1E-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes Dev. 30, 798\u2013811 (2016).","journal-title":"Genes Dev."},{"key":"2499_CR213","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","volume":"36","author":"J Araujo","year":"2010","unstructured":"Araujo, J. & Logothetis, C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat. Rev. 36, 492\u2013500 (2010).","journal-title":"Cancer Treat. Rev."},{"key":"2499_CR214","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/annonc\/mdw607","volume":"28","author":"TRJ Evans","year":"2017","unstructured":"Evans, T. R. J. et al. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Ann. Oncol. 28, 354\u2013361 (2017).","journal-title":"Ann. Oncol."},{"key":"2499_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08115-8","volume":"10","author":"Y Kano","year":"2019","unstructured":"Kano, Y. et al. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nat. Commun. 10, 224 (2019).","journal-title":"Nat. Commun."},{"key":"2499_CR216","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10555-020-09918-2","volume":"39","author":"L Buday","year":"2020","unstructured":"Buday, L. & Vas, V. Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation. Cancer Metastasis Rev. 39, 1067\u20131073 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"2499_CR217","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s42004-024-01105-6","volume":"7","author":"P Baumann","year":"2024","unstructured":"Baumann, P. & Jin, Y. Far-reaching effects of tyrosine64 phosphorylation on Ras revealed with BeF(3)(-) complexes. Commun. Chem. 7, 19 (2024).","journal-title":"Commun. Chem."},{"key":"2499_CR218","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","volume":"20","author":"RJ Nichols","year":"2018","unstructured":"Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. 20, 1064\u20131073 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR219","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","volume":"24","author":"DA Ruess","year":"2018","unstructured":"Ruess, D. A. et al. Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase. Nat. Med. 24, 954\u2013960 (2018).","journal-title":"Nat. Med."},{"key":"2499_CR220","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9859","volume":"6","author":"S Bunda","year":"2015","unstructured":"Bunda, S. et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat. Commun. 6, 8859 (2015).","journal-title":"Nat. Commun."},{"key":"2499_CR221","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s43018-021-00184-x","volume":"2","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay, S., Vander Heiden, M. G. & McCormick, F. The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. Nat. Cancer 2, 271\u2013283 (2021).","journal-title":"Nat. Cancer"},{"key":"2499_CR222","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","volume":"15","author":"H Wu","year":"2024","unstructured":"Wu, H. et al. Emerging mechanisms and promising approaches in pancreatic cancer metabolism. Cell Death Dis. 15, 553 (2024).","journal-title":"Cell Death Dis."},{"key":"2499_CR223","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02216-3","volume":"24","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Targeting KRAS: from metabolic regulation to cancer treatment. Mol. Cancer 24, 9 (2025).","journal-title":"Mol. Cancer"},{"key":"2499_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101162","volume":"4","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep. Med. 4, 101162 (2023).","journal-title":"Cell Rep. Med."},{"key":"2499_CR225","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio, C. et al. Functional expression of sodium-glucose transporters in cancer. Proc. Natl Acad. Sci. USA 112, E4111\u2013E4119 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR226","doi-asserted-by":"publisher","first-page":"100077","DOI":"10.1016\/j.cellin.2023.100077","volume":"2","author":"D Guo","year":"2023","unstructured":"Guo, D., Meng, Y., Jiang, X. & Lu, Z. Hexokinases in cancer and other pathologies. Cell Insight 2, 100077 (2023).","journal-title":"Cell Insight"},{"key":"2499_CR227","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1053\/j.gastro.2024.05.005","volume":"167","author":"S Rauth","year":"2024","unstructured":"Rauth, S., Malafa, M., Ponnusamy, M. P. & Batra, S. K. Emerging trends in gastrointestinal cancer targeted therapies: harnessing tumor microenvironment, immune factors, and metabolomics insights. Gastroenterology 167, 867\u2013884 (2024).","journal-title":"Gastroenterology"},{"key":"2499_CR228","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174264","volume":"10","author":"ZC Nwosu","year":"2025","unstructured":"Nwosu, Z. C. et al. Multidimensional analyses identify genes of high priority for pancreatic cancer research. JCI Insight 10, e174264 (2025).","journal-title":"JCI Insight"},{"key":"2499_CR229","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cmet.2020.12.015","volume":"33","author":"D Xu","year":"2021","unstructured":"Xu, D. et al. The evolving landscape of noncanonical functions of metabolic enzymes in cancer and other pathologies. Cell Metab. 33, 33\u201350 (2021).","journal-title":"Cell Metab."},{"key":"2499_CR230","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang, D. et al. Metabolic regulation of gene expression by histone lactylation. Nature 574, 575\u2013580 (2019).","journal-title":"Nature"},{"key":"2499_CR231","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.molcel.2025.02.011","volume":"85","author":"M Iozzo","year":"2025","unstructured":"Iozzo, M., Pardella, E., Giannoni, E. & Chiarugi, P. The role of protein lactylation: a kaleidoscopic post-translational modification in cancer. Mol. Cell 85, 1263\u20131279 (2025).","journal-title":"Mol. Cell"},{"key":"2499_CR232","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0516-4","volume":"15","author":"H Fukushima","year":"2016","unstructured":"Fukushima, H. et al. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells. Mol. Cancer 15, 32 (2016).","journal-title":"Mol. Cancer"},{"key":"2499_CR233","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1614","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Song, H., Li, M. & Lu, P. Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: Oncometabolite fuels oncogenic transcription. Clin. Transl. Med. 14, e1614 (2024).","journal-title":"Clin. Transl. Med."},{"key":"2499_CR234","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187024","volume":"135","author":"K Sun","year":"2025","unstructured":"Sun, K. et al. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. J. Clin. Invest. 135, e187024 (2025).","journal-title":"J. Clin. Invest."},{"key":"2499_CR235","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.cmet.2025.07.008","volume":"37","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. Cell Metab. 37, 1907\u20131925.e14 (2025).","journal-title":"Cell Metab."},{"key":"2499_CR236","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02008-9","volume":"23","author":"F Li","year":"2024","unstructured":"Li, F. et al. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol. Cancer 23, 90 (2024).","journal-title":"Mol. Cancer"},{"key":"2499_CR237","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tem.2019.03.003","volume":"30","author":"E Bernfeld","year":"2019","unstructured":"Bernfeld, E. & Foster, D. A. Glutamine as an essential amino acid for KRas-driven cancer cells. Trends Endocrinol. Metab. 30, 357\u2013368 (2019).","journal-title":"Trends Endocrinol. Metab."},{"key":"2499_CR238","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101\u2013105 (2013).","journal-title":"Nature"},{"key":"2499_CR239","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1111\/jcmm.13202","volume":"21","author":"W Li","year":"2017","unstructured":"Li, W. et al. HIF-2\u03b1 regulates non-canonical glutamine metabolism via activation of PI3K\/mTORC2 pathway in human pancreatic ductal adenocarcinoma. J. Cell Mol. Med. 21, 2896\u20132908 (2017).","journal-title":"J. Cell Mol. Med."},{"key":"2499_CR240","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1172\/JCI127515","volume":"130","author":"NS Sharma","year":"2020","unstructured":"Sharma, N. S. et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J. Clin. Invest. 130, 451\u2013465 (2020).","journal-title":"J. Clin. Invest."},{"key":"2499_CR241","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05891-2","volume":"616","author":"M-S Lee","year":"2023","unstructured":"Lee, M.-S. et al. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Nature 616, 339\u2013347 (2023).","journal-title":"Nature"},{"key":"2499_CR242","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43018-023-00647-3","volume":"5","author":"J Encarnaci\u00f3n-Rosado","year":"2024","unstructured":"Encarnaci\u00f3n-Rosado, J. et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nat. Cancer 5, 85\u201399 (2024).","journal-title":"Nat. Cancer"},{"key":"2499_CR243","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41586-025-08917-z","volume":"642","author":"C Cheng","year":"2025","unstructured":"Cheng, C. et al. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Nature 642, 776\u2013784 (2025).","journal-title":"Nature"},{"key":"2499_CR244","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41575-021-00431-7","volume":"18","author":"J Encarnaci\u00f3n-Rosado","year":"2021","unstructured":"Encarnaci\u00f3n-Rosado, J. & Kimmelman, A. C. Harnessing metabolic dependencies in pancreatic cancers. Nat. Rev. Gastroenterol. Hepatol. 18, 482\u2013492 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2499_CR245","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf9284","volume":"9","author":"S Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay, S. et al. Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer. Sci. Adv. 9, eadf9284 (2023).","journal-title":"Sci. Adv."},{"key":"2499_CR246","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/2159-8290.CD-14-0362","volume":"4","author":"A Yang","year":"2014","unstructured":"Yang, A. et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 4, 905\u2013913 (2014).","journal-title":"Cancer Discov."},{"key":"2499_CR247","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.devcel.2020.06.025","volume":"54","author":"C Ibar","year":"2020","unstructured":"Ibar, C. & Irvine, K. D. Integration of Hippo-YAP signaling with metabolism. Dev. Cell 54, 256\u2013267 (2020).","journal-title":"Dev. Cell"},{"key":"2499_CR248","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.178535","volume":"9","author":"W Yang","year":"2024","unstructured":"Yang, W. et al. YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis. JCI Insight 9, e178535 (2024).","journal-title":"JCI Insight"},{"key":"2499_CR249","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41588-020-00727-5","volume":"52","author":"A Balmain","year":"2020","unstructured":"Balmain, A. The critical roles of somatic mutations and environmental tumor-promoting agents in cancer risk. Nat. Genet. 52, 1139\u20131143 (2020).","journal-title":"Nat. Genet."},{"key":"2499_CR250","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","volume":"616","author":"W Hill","year":"2023","unstructured":"Hill, W. et al. Lung adenocarcinoma promotion by air pollutants. Nature 616, 159\u2013167 (2023).","journal-title":"Nature"},{"key":"2499_CR251","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/2159-8290.CD-24-1379","volume":"15","author":"YR Li","year":"2025","unstructured":"Li, Y. R. et al. Long term latency of highly mutated cells in normal mouse skin is reversed by exposure to tumor promoters and chronic tissue damage. Cancer Discov. 15, 1115\u20131128 (2025).","journal-title":"Cancer Discov."},{"key":"2499_CR252","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-24-0128","volume":"14","author":"W Hill","year":"2024","unstructured":"Hill, W., Weeden, C. E. & Swanton, C. Tumor promoters and opportunities for molecular cancer prevention. Cancer Discov. 14, 1154\u20131160 (2024).","journal-title":"Cancer Discov."},{"key":"2499_CR253","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/archinternmed.2010.63","volume":"170","author":"AA Arslan","year":"2010","unstructured":"Arslan, A. A. et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch. Intern. Med. 170, 791\u2013802 (2010).","journal-title":"Arch. Intern. Med."},{"key":"2499_CR254","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1158\/1078-0432.CCR-14-2385","volume":"21","author":"V Rebours","year":"2015","unstructured":"Rebours, V. et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin. Cancer Res. 21, 3522\u20133528 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR255","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan, B. et al. Body fatness and cancer\u2014viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794\u2013798 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2499_CR256","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1210\/endrev\/bnz014","volume":"41","author":"IC Lega","year":"2019","unstructured":"Lega, I. C. & Lipscombe, L. L. Review: diabetes, obesity, and cancer\u2014pathophysiology and clinical implications. Endocr. Rev. 41, 33\u201352 (2019).","journal-title":"Endocr. Rev."},{"key":"2499_CR257","doi-asserted-by":"publisher","first-page":"e2310002","DOI":"10.1001\/jamanetworkopen.2023.10002","volume":"6","author":"HA Loomans-Kropp","year":"2023","unstructured":"Loomans-Kropp, H. A. & Umar, A. Analysis of body mass index in early and middle adulthood and estimated risk of gastrointestinal cancer. JAMA Netw. Open 6, e2310002 (2023).","journal-title":"JAMA Netw. Open"},{"key":"2499_CR258","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41431-023-01301-3","volume":"31","author":"JG Maina","year":"2023","unstructured":"Maina, J. G. et al. Abdominal obesity is a more important causal risk factor for pancreatic cancer than overall obesity. Eur. J. Hum. Genet. 31, 962\u2013966 (2023).","journal-title":"Eur. J. Hum. Genet."},{"key":"2499_CR259","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein, A. P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat. Rev. Gastroenterol. Hepatol. 18, 493\u2013502 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2499_CR260","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13799","volume":"25","author":"M Mandic","year":"2024","unstructured":"Mandic, M. et al. Overcoming underestimation of the association of excess weight with pancreatic cancer due to prediagnostic weight loss: umbrella review of systematic reviews, meta-analyses, and pooled-analyses. Obes. Rev. 25, e13799 (2024).","journal-title":"Obes. Rev."},{"key":"2499_CR261","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/jgh.16477","volume":"39","author":"ZQ Zhan","year":"2024","unstructured":"Zhan, Z. Q. et al. Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta-analysis of 31 prospective cohorts and Mendelian randomization study. J. Gastroenterol. Hepatol. 39, 630\u2013641 (2024).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2499_CR262","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1053\/j.gastro.2021.09.070","volume":"162","author":"JH Park","year":"2022","unstructured":"Park, J. H. et al. Changes in metabolic syndrome status are associated with altered risk of pancreatic cancer: a Nationwide Cohort Study. Gastroenterology 162, 509\u2013520.e507 (2022).","journal-title":"Gastroenterology"},{"key":"2499_CR263","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cgh.2015.09.036","volume":"14","author":"K Majumder","year":"2016","unstructured":"Majumder, K., Gupta, A., Arora, N., Singh, P. P. & Singh, S. Premorbid obesity and mortality in patients with pancreatic cancer: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 14, 355\u2013368.e (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2499_CR264","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/1940-6207.CAPR-13-0065","volume":"6","author":"DW Dawson","year":"2013","unstructured":"Dawson, D. W. et al. High fat, high calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev. Res. (Philos.) 6, 1064\u20131073 (2013).","journal-title":"Cancer Prev. Res. (Philos.)"},{"key":"2499_CR265","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302228","volume":"6","author":"CF Ruiz","year":"2023","unstructured":"Ruiz, C. F., Garcia, C., Jacox, J. B., Lawres, L. & Muzumdar, M. D. Decoding the obesity-cancer connection: lessons from preclinical models of pancreatic adenocarcinoma. Life Sci. Alliance 6, e202302228 (2023).","journal-title":"Life Sci. Alliance"},{"key":"2499_CR266","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1053\/j.gastro.2013.08.018","volume":"145","author":"B Philip","year":"2013","unstructured":"Philip, B. et al. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 145, 1449\u20131458 (2013).","journal-title":"Gastroenterology"},{"key":"2499_CR267","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0701-0","volume":"16","author":"K Chen","year":"2017","unstructured":"Chen, K. et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol. Cancer 16, 131 (2017).","journal-title":"Mol. Cancer"},{"key":"2499_CR268","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10555-021-09977-z","volume":"40","author":"G Eibl","year":"2021","unstructured":"Eibl, G. & Rozengurt, E. Metformin: review of epidemiology and mechanisms of action in pancreatic cancer. Cancer Metastasis Rev. 40, 865\u2013878 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2499_CR269","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1158\/0008-5472.CAN-23-1045","volume":"84","author":"V Pita-Grisanti","year":"2024","unstructured":"Pita-Grisanti, V. et al. Physical activity decreases inflammation and delays the development of obesity-associated pancreatic ductal adenocarcinoma. Cancer Res. 84, 3058\u20133071 (2024).","journal-title":"Cancer Res."},{"key":"2499_CR270","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","volume":"40","author":"E Kurz","year":"2022","unstructured":"Kurz, E. et al. Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell 40, 720\u2013737.e725 (2022).","journal-title":"Cancer Cell"},{"key":"2499_CR271","doi-asserted-by":"publisher","first-page":"F9","DOI":"10.1530\/ERC-12-0105","volume":"19","author":"Y Cui","year":"2012","unstructured":"Cui, Y. & Andersen, D. K. Diabetes and pancreatic cancer. Endocr. Relat. Cancer 19, F9\u2013F26 (2012).","journal-title":"Endocr. Relat. Cancer"},{"key":"2499_CR272","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1158\/2159-8290.CD-21-1672","volume":"12","author":"G Fonteneau","year":"2022","unstructured":"Fonteneau, G. et al. Stress granules determine the development of obesity-associated pancreatic cancer. Cancer Discov. 12, 1984\u20132005 (2022).","journal-title":"Cancer Discov."},{"key":"2499_CR273","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.cmet.2023.10.003","volume":"35","author":"AMY Zhang","year":"2023","unstructured":"Zhang, A. M. Y. et al. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Cell Metab. 35, 2119\u20132135.e2115 (2023).","journal-title":"Cell Metab."},{"key":"2499_CR274","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/aje\/kwv041","volume":"182","author":"RZ Stolzenberg-Solomon","year":"2015","unstructured":"Stolzenberg-Solomon, R. Z. et al. Circulating leptin and risk of pancreatic cancer: a pooled analysis from 3 cohorts. Am. J. Epidemiol. 182, 187\u2013197 (2015).","journal-title":"Am. J. Epidemiol."},{"key":"2499_CR275","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1158\/0008-5472.CAN-16-1699","volume":"76","author":"A Babic","year":"2016","unstructured":"Babic, A. et al. Pancreatic cancer risk associated with prediagnostic plasma levels of leptin and leptin receptor genetic polymorphisms. Cancer Res 76, 7160\u20137167 (2016).","journal-title":"Cancer Res"},{"key":"2499_CR276","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/s42255-024-01045-4","volume":"6","author":"S Choi","year":"2024","unstructured":"Choi, S. et al. Hippo\u2013YAP\/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass. Nat. Metab. 6, 847\u2013860 (2024).","journal-title":"Nat. Metab."},{"key":"2499_CR277","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nature17662","volume":"533","author":"J Li","year":"2016","unstructured":"Li, J. et al. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature 533, 411\u2013415 (2016).","journal-title":"Nature"},{"key":"2499_CR278","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1878-0261.12815","volume":"15","author":"K Takahashi","year":"2021","unstructured":"Takahashi, K. et al. Neurotensin receptor 1 signaling promotes pancreatic cancer progression. Mol. Oncol. 15, 151\u2013166 (2021).","journal-title":"Mol. Oncol."},{"key":"2499_CR279","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/oby.24066","volume":"32","author":"F Farahmand","year":"2024","unstructured":"Farahmand, F. et al. Dopamine production in neurotensin receptor 1 neurons is required for diet-induced obesity and increased day eating on a high-fat diet. Obesity (Silver Spring) 32, 1448\u20131452 (2024).","journal-title":"Obesity (Silver Spring)"},{"key":"2499_CR280","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1152\/physrev.00013.2014","volume":"95","author":"DA Sandoval","year":"2015","unstructured":"Sandoval, D. A. & D\u2019Alessio, D. A. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95, 513\u2013548 (2015).","journal-title":"Physiol. Rev."},{"key":"2499_CR281","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ijo.2015.220","volume":"40","author":"ME Lean","year":"2016","unstructured":"Lean, M. E. & Malkova, D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence?. Int. J. Obes. (Lond). 40, 622\u2013632 (2016).","journal-title":"Int. J. Obes. (Lond)."},{"key":"2499_CR282","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.cell.2020.03.062","volume":"181","author":"KM Chung","year":"2020","unstructured":"Chung, K. M. et al. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma. Cell 181, 832\u2013847.e818 (2020).","journal-title":"Cell"},{"key":"2499_CR283","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cmet.2019.07.003","volume":"30","author":"AMY Zhang","year":"2019","unstructured":"Zhang, A. M. Y. et al. Endogenous hyperinsulinemia contributes to pancreatic cancer development. Cell Metab. 30, 403\u2013404 (2019).","journal-title":"Cell Metab."},{"key":"2499_CR284","first-page":"1632","volume":"62","author":"S Guha","year":"2002","unstructured":"Guha, S., Rey, O. & Rozengurt, E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 62, 1632\u20131640 (2002).","journal-title":"Cancer Res."},{"key":"2499_CR285","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","volume":"41","author":"D Hanahan","year":"2023","unstructured":"Hanahan, D. & Monje, M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell 41, 573\u2013580 (2023).","journal-title":"Cancer Cell"},{"key":"2499_CR286","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41586-023-05968-y","volume":"618","author":"R Mancusi","year":"2023","unstructured":"Mancusi, R. & Monje, M. The neuroscience of cancer. Nature 618, 467\u2013479 (2023).","journal-title":"Nature"},{"key":"2499_CR287","doi-asserted-by":"publisher","first-page":"1421067","DOI":"10.3389\/fonc.2024.1421067","volume":"14","author":"Y Sun","year":"2024","unstructured":"Sun, Y., Jiang, W., Liao, X. & Wang, D. Hallmarks of perineural invasion in pancreatic ductal adenocarcinoma: new biological dimensions. Front. Oncol. 14, 1421067 (2024).","journal-title":"Front. Oncol."},{"key":"2499_CR288","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrgastro.2015.166","volume":"12","author":"IE Demir","year":"2015","unstructured":"Demir, I. E., Friess, H. & Ceyhan, G. O. Neural plasticity in pancreatitis and pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 12, 649\u2013659 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2499_CR289","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.gastro.2008.09.029","volume":"136","author":"GO Ceyhan","year":"2009","unstructured":"Ceyhan, G. O. et al. Pancreatic neuropathy and neuropathic pain-a comprehensive pathomorphological study of 546 cases. Gastroenterology 136, 177\u2013186.e171 (2009).","journal-title":"Gastroenterology"},{"key":"2499_CR290","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41416-023-02539-w","volume":"130","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Tumour-associated macrophages and Schwann cells promote perineural invasion via paracrine loop in pancreatic ductal adenocarcinoma. Br. J. Cancer 130, 542\u2013554 (2024).","journal-title":"Br. J. Cancer"},{"key":"2499_CR291","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.1111\/febs.17280","volume":"291","author":"B Kizil","year":"2024","unstructured":"Kizil, B., De Virgiliis, F. & Scheiermann, C. Neural control of tumor immunity. FEBS J. 291, 4670\u20134679 (2024).","journal-title":"FEBS J."},{"key":"2499_CR292","doi-asserted-by":"publisher","DOI":"10.1126\/science.1236361","volume":"341","author":"C Magnon","year":"2013","unstructured":"Magnon, C. et al. Autonomic nerve development contributes to prostate cancer progression. Science 341, 1236361 (2013).","journal-title":"Science"},{"key":"2499_CR293","doi-asserted-by":"publisher","first-page":"250ra115","DOI":"10.1126\/scitranslmed.3009569","volume":"6","author":"CM Zhao","year":"2014","unstructured":"Zhao, C. M. et al. Denervation suppresses gastric tumorigenesis. Sci. Transl. Med. 6, 250ra115 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2499_CR294","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1073\/pnas.1512603113","volume":"113","author":"JL Saloman","year":"2016","unstructured":"Saloman, J. L. et al. Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Proc. Natl Acad. Sci. USA 113, 3078\u20133083 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR295","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-16-0899","volume":"77","author":"S Sinha","year":"2017","unstructured":"Sinha, S. et al. PanIN neuroendocrine cells promote tumorigenesis via neuronal crosstalk. Cancer Res. 77, 1868\u20131879 (2017).","journal-title":"Cancer Res."},{"key":"2499_CR296","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-18-1398","volume":"9","author":"S Faulkner","year":"2019","unstructured":"Faulkner, S., Jobling, P., March, B., Jiang, C. C. & Hondermarck, H. Tumor neurobiology and the war of nerves in cancer. Cancer Discov. 9, 702\u2013710 (2019).","journal-title":"Cancer Discov."},{"key":"2499_CR297","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1158\/0008-5472.CAN-16-1701","volume":"78","author":"JK Allen","year":"2018","unstructured":"Allen, J. K. et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Res. 78, 3233\u20133242 (2018).","journal-title":"Cancer Res."},{"key":"2499_CR298","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1158\/0008-5472.CAN-15-2790","volume":"78","author":"C Bressy","year":"2018","unstructured":"Bressy, C. et al. LIF drives neural remodeling in pancreatic cancer and offers a new candidate biomarker. Cancer Res. 78, 909\u2013921 (2018).","journal-title":"Cancer Res."},{"key":"2499_CR299","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41586-019-1219-y","volume":"569","author":"P Mauffrey","year":"2019","unstructured":"Mauffrey, P. et al. Progenitors from the central nervous system drive neurogenesis in cancer. Nature 569, 672\u2013678 (2019).","journal-title":"Nature"},{"key":"2499_CR300","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cell.2020.10.016","volume":"183","author":"RS Banh","year":"2020","unstructured":"Banh, R. S. et al. Neurons release serine to support mRNA translation in pancreatic cancer. Cell 183, 1202\u20131218.e1225 (2020).","journal-title":"Cell"},{"key":"2499_CR301","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ags3.12459","volume":"5","author":"T Wakiya","year":"2021","unstructured":"Wakiya, T., Ishido, K., Yoshizawa, T., Kanda, T. & Hakamada, K. Roles of the nervous system in pancreatic cancer. Ann. Gastroenterol. Surg. 5, 623\u2013633 (2021).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"2499_CR302","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.gastro.2008.09.029","volume":"136","author":"GO Ceyhan","year":"2009","unstructured":"Ceyhan, G. O. et al. Pancreatic neuropathy and neuropathic pain\u2014a comprehensive pathomorphological study of 546 cases. Gastroenterology 136, 177\u2013186.e1 (2009).","journal-title":"Gastroenterology"},{"key":"2499_CR303","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/0008-5472.CAN-13-2050","volume":"74","author":"RE Stopczynski","year":"2014","unstructured":"Stopczynski, R. E. et al. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res. 74, 1718\u20131727 (2014).","journal-title":"Cancer Res."},{"key":"2499_CR304","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41568-019-0237-2","volume":"20","author":"AH Zahalka","year":"2020","unstructured":"Zahalka, A. H. & Frenette, P. S. Nerves in cancer. Nat. Rev. Cancer 20, 143\u2013157 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR305","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41388-020-01578-4","volume":"40","author":"X Tan","year":"2021","unstructured":"Tan, X. et al. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. Oncogene 40, 899\u2013908 (2021).","journal-title":"Oncogene"},{"key":"2499_CR306","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s12264-023-01082-1","volume":"39","author":"B Ni","year":"2023","unstructured":"Ni, B. et al. Crosstalk between peripheral innervation and pancreatic ductal adenocarcinoma. Neurosci. Bull. 39, 1717\u20131731 (2023).","journal-title":"Neurosci. Bull."},{"key":"2499_CR307","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","volume":"622","author":"AM Globig","year":"2023","unstructured":"Globig, A. M. et al. The \u03b2(1)-adrenergic receptor links sympathetic nerves to T\u2009cell exhaustion. Nature 622, 383\u2013392 (2023).","journal-title":"Nature"},{"key":"2499_CR308","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41573-024-01017-z","volume":"23","author":"D Yaniv","year":"2024","unstructured":"Yaniv, D., Mattson, B., Talbot, S., Gleber-Netto, F. O. & Amit, M. Targeting the peripheral neural-tumour microenvironment for cancer therapy. Nat. Rev. Drug Discov. 23, 780\u2013796 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2499_CR309","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147276","volume":"131","author":"SM Gysler","year":"2021","unstructured":"Gysler, S. M. & Drapkin, R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. J. Clin. Invest. 131, e147276 (2021).","journal-title":"J. Clin. Invest."},{"key":"2499_CR310","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62299-4","volume":"16","author":"H Haidar","year":"2025","unstructured":"Haidar, H. et al. Neural function of Netrin-1 in precancerous lesions of the pancreas. Nat. Commun. 16, 7094 (2025).","journal-title":"Nat. Commun."},{"key":"2499_CR311","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/1535-7163.MCT-12-0809","volume":"12","author":"K Guo","year":"2013","unstructured":"Guo, K. et al. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol. Cancer Ther. 12, 264\u2013273 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR312","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccell.2017.11.007","volume":"33","author":"BW Renz","year":"2018","unstructured":"Renz, B. W. et al. \u03b22 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 33, 75\u201390.e77 (2018).","journal-title":"Cancer Cell"},{"key":"2499_CR313","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/1541-7786.MCR-24-0785","volume":"23","author":"X Sun","year":"2025","unstructured":"Sun, X. et al. Stress and obesity signaling converge on CREB phosphorylation to promote pancreatic cancer. Mol. Cancer Res. 23, 236\u2013249 (2025).","journal-title":"Mol. Cancer Res."},{"key":"2499_CR314","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler, F. et al. Cancer neuroscience: state of the field, emerging directions. Cell 186, 1689\u20131707 (2023).","journal-title":"Cell"},{"key":"2499_CR315","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3389\/fonc.2020.01492","volume":"10","author":"S Dai","year":"2020","unstructured":"Dai, S. et al. Chronic stress promotes cancer development. Front. Oncol. 10, 1492 (2020).","journal-title":"Front. Oncol."},{"key":"2499_CR316","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fendo.2018.00498","volume":"9","author":"A Stengel","year":"2018","unstructured":"Stengel, A. & Tach\u00e9, Y. Gut-brain neuroendocrine signaling under conditions of stress-focus on food intake-regulatory mediators. Front Endocrinol. 9, 498\u2013498 (2018).","journal-title":"Front Endocrinol."},{"key":"2499_CR317","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fnbeh.2018.00127","volume":"12","author":"LD Godoy","year":"2018","unstructured":"Godoy, L. D., Rossignoli, M. T., Delfino-Pereira, P., Garcia-Cairasco, N. & de Lima Umeoka, E. H. A comprehensive overview on stress neurobiology: basic concepts and clinical implications. Front. Behav. Neurosci. 12, 127 (2018).","journal-title":"Front. Behav. Neurosci."},{"key":"2499_CR318","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41568-021-00395-5","volume":"21","author":"A Eckerling","year":"2021","unstructured":"Eckerling, A., Ricon-Becker, I., Sorski, L., Sandbank, E. & Ben-Eliyahu, S. Stress and cancer: mechanisms, significance and future directions. Nat. Rev. Cancer 21, 767\u2013785 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR319","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10549-011-1348-y","volume":"130","author":"KS Madden","year":"2011","unstructured":"Madden, K. S., Szpunar, M. J. & Brown, E. B. \u03b2-Adrenergic receptors (\u03b2-AR) regulate VEGF and IL-6 production by divergent pathways in high \u03b2-AR-expressing breast cancer cell lines. Breast Cancer Res. Treat. 130, 747\u2013758 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"2499_CR320","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1200\/JCO.2009.26.9357","volume":"28","author":"SK Lutgendorf","year":"2010","unstructured":"Lutgendorf, S. K., Sood, A. K. & Antoni, M. H. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J. Clin. Oncol. 28, 4094\u20134099 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2499_CR321","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole, S. W. & Sood, A. K. Molecular pathways: beta-adrenergic signaling in cancer. Clin. Cancer Res 18, 1201\u20131206 (2012).","journal-title":"Clin. Cancer Res"},{"key":"2499_CR322","first-page":"874","volume":"123","author":"S Hassan","year":"2013","unstructured":"Hassan, S. et al. Behavioral stress accelerates prostate cancer development in mice. J. Clin. Invest. 123, 874\u2013886 (2013).","journal-title":"J. Clin. Invest."},{"key":"2499_CR323","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bbi.2012.01.013","volume":"26","author":"DM Lamkin","year":"2012","unstructured":"Lamkin, D. M. et al. Chronic stress enhances progression of acute lymphoblastic leukemia via \u03b2-adrenergic signaling. Brain Behav. Immun. 26, 635\u2013641 (2012).","journal-title":"Brain Behav. Immun."},{"key":"2499_CR324","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1158\/1078-0432.CCR-15-0101","volume":"22","author":"D Lu","year":"2016","unstructured":"Lu, D. et al. Stress-related signaling pathways in lethal and non-lethal prostate cancer. Clin. Cancer Res. 22, 765\u2013772 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR325","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10634","volume":"7","author":"CP Le","year":"2016","unstructured":"Le, C. P. et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat. Commun. 7, 10634 (2016).","journal-title":"Nat. Commun."},{"key":"2499_CR326","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2020.11.040","volume":"145","author":"S Zanini","year":"2021","unstructured":"Zanini, S. et al. A review of lifestyle and environment risk factors for pancreatic cancer. Eur. J. Cancer 145, 53\u201370 (2021).","journal-title":"Eur. J. Cancer"},{"key":"2499_CR327","doi-asserted-by":"publisher","first-page":"J108","DOI":"10.1136\/bmj.j108","volume":"356","author":"GD Batty","year":"2017","unstructured":"Batty, G. D., Russ, T. C., Stamatakis, E. & Kivim\u00e4ki, M. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. Br. Med. J. 356, J108 (2017).","journal-title":"Br. Med. J."},{"key":"2499_CR328","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.pan.2016.03.005","volume":"16","author":"LI Partecke","year":"2016","unstructured":"Partecke, L. I. et al. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Pancreatology 16, 423\u2013433 (2016).","journal-title":"Pancreatology"},{"key":"2499_CR329","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbi.2014.02.019","volume":"40","author":"C Kim-Fuchs","year":"2014","unstructured":"Kim-Fuchs, C. et al. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav. Immun. 40, 40\u201347 (2014).","journal-title":"Brain Behav. Immun."},{"key":"2499_CR330","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2174\/15665240113139990055","volume":"13","author":"T Shan","year":"2013","unstructured":"Shan, T. et al. \u03b22-AR-HIF-1\u03b1: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis. Curr. Mol. Med. 13, 1023\u20131034 (2013).","journal-title":"Curr. Mol. Med."},{"key":"2499_CR331","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41388-019-1006-0","volume":"39","author":"S-H Jiang","year":"2020","unstructured":"Jiang, S.-H., Hu, L.-P., Wang, X., Li, J. & Zhang, Z.-G. Neurotransmitters: emerging targets in cancer. Oncogene 39, 503\u2013515 (2020).","journal-title":"Oncogene"},{"key":"2499_CR332","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1158\/0008-5472.CAN-17-0108","volume":"77","author":"R Udumyan","year":"2017","unstructured":"Udumyan, R. et al. Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma. Cancer Res. 77, 3700\u20133707 (2017).","journal-title":"Cancer Res."},{"key":"2499_CR333","doi-asserted-by":"publisher","first-page":"1137791","DOI":"10.3389\/fphar.2023.1137791","volume":"14","author":"A Le Bozec","year":"2023","unstructured":"Le Bozec, A. et al. Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC). Front. Pharm. 14, 1137791 (2023).","journal-title":"Front. Pharm."},{"key":"2499_CR334","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41568-023-00556-8","volume":"23","author":"C Magnon","year":"2023","unstructured":"Magnon, C. & Hondermarck, H. The neural addiction of cancer. Nat. Rev. Cancer 23, 317\u2013334 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR335","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.bbrc.2017.09.146","volume":"493","author":"J Pu","year":"2017","unstructured":"Pu, J. et al. Adrenaline promotes epithelial-to-mesenchymal transition via HuR-TGF\u03b2 regulatory axis in pancreatic cancer cells and the implication in cancer prognosis. Biochem. Biophys. Res. Commun. 493, 1273\u20131279 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2499_CR336","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/aje\/kwt045","volume":"178","author":"J Huang","year":"2013","unstructured":"Huang, J., Valdimarsd\u00f3ttir, U., Fall, K., Ye, W. & Fang, F. Pancreatic cancer risk after loss of a child: a register-based study in Sweden during 1991\u20132009. Am. J. Epidemiol. 178, 582\u2013589 (2013).","journal-title":"Am. J. Epidemiol."},{"key":"2499_CR337","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2024.01.013","volume":"42","author":"XY He","year":"2024","unstructured":"He, X. Y. et al. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell 42, 474\u2013486.e12 (2024).","journal-title":"Cancer Cell"},{"key":"2499_CR338","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-19-2689","volume":"80","author":"MW Yang","year":"2020","unstructured":"Yang, M. W. et al. Perineural invasion reprograms the immune microenvironment through cholinergic signaling in pancreatic ductal adenocarcinoma. Cancer Res 80, 1991\u20132003 (2020).","journal-title":"Cancer Res"},{"key":"2499_CR339","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/2159-8290.CD-18-0046","volume":"8","author":"BW Renz","year":"2018","unstructured":"Renz, B. W. et al. Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness. Cancer Discov. 8, 1458\u20131473 (2018).","journal-title":"Cancer Discov."},{"key":"2499_CR340","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1745691614568352","volume":"10","author":"J Holt-Lunstad","year":"2015","unstructured":"Holt-Lunstad, J., Smith, T. B., Baker, M., Harris, T. & Stephenson, D. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspect. Psychol. Sci. 10, 227\u2013237 (2015).","journal-title":"Perspect. Psychol. Sci."},{"key":"2499_CR341","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000316","volume":"7","author":"J Holt-Lunstad","year":"2010","unstructured":"Holt-Lunstad, J., Smith, T. B. & Layton, J. B. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 7, e1000316 (2010).","journal-title":"PLoS Med."},{"key":"2499_CR342","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/cncr.30440","volume":"123","author":"CH Kroenke","year":"2017","unstructured":"Kroenke, C. H. et al. Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project. Cancer 123, 1228\u20131237 (2017).","journal-title":"Cancer"},{"key":"2499_CR343","doi-asserted-by":"publisher","first-page":"113868","DOI":"10.1016\/j.psychres.2021.113868","volume":"299","author":"SL Kraav","year":"2021","unstructured":"Kraav, S. L., Lehto, S. M., Kauhanen, J., Hantunen, S. & Tolmunen, T. Loneliness and social isolation increase cancer incidence in a cohort of Finnish middle-aged men. A longitudinal study. Psychiatry Res. 299, 113868 (2021).","journal-title":"Psychiatry Res."},{"key":"2499_CR344","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad126","volume":"164","author":"L Hilakivi-Clarke","year":"2023","unstructured":"Hilakivi-Clarke, L. & de Oliveira Andrade, F. Social isolation and breast cancer. Endocrinology 164, bqad126 (2023).","journal-title":"Endocrinology"},{"key":"2499_CR345","doi-asserted-by":"publisher","first-page":"973640","DOI":"10.3389\/fpsyg.2022.973640","volume":"13","author":"Y Liang","year":"2022","unstructured":"Liang, Y., Hao, G., Wu, M. & Hou, L. Social isolation in adults with cancer: an evolutionary concept analysis. Front. Psychol. 13, 973640 (2022).","journal-title":"Front. Psychol."},{"key":"2499_CR346","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.conb.2021.03.005","volume":"68","author":"N Zilkha","year":"2021","unstructured":"Zilkha, N., Sofer, Y., Kashash, Y. & Kimchi, T. The social network: neural control of sex differences in reproductive behaviors, motivation, and response to social isolation. Curr. Opin. Neurobiol. 68, 137\u2013151 (2021).","journal-title":"Curr. Opin. Neurobiol."},{"key":"2499_CR347","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.18726","volume":"5","author":"L Senst","year":"2016","unstructured":"Senst, L., Baimoukhametova, D., Sterley, T. L. & Bains, J. S. Sexually dimorphic neuronal responses to social isolation. Elife 5, e18726 (2016).","journal-title":"Elife"},{"key":"2499_CR348","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13293-016-0122-6","volume":"8","author":"L Wang","year":"2017","unstructured":"Wang, L., Goebel-Stengel, M., Yuan, P.-Q., Stengel, A. & Tach\u00e9, Y. Corticotropin-releasing factor overexpression in mice abrogates sex differences in body weight, visceral fat, and food intake response to a fast and alters levels of feeding regulatory hormones. Biol. Sex. Differ. 8, 2 (2017).","journal-title":"Biol. Sex. Differ."},{"key":"2499_CR349","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nm.4350","volume":"23","author":"MP Czech","year":"2017","unstructured":"Czech, M. P. Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23, 804\u2013814 (2017).","journal-title":"Nat. Med."},{"key":"2499_CR350","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1146\/annurev-psych-010418-102936","volume":"70","author":"AJ Tomiyama","year":"2019","unstructured":"Tomiyama, A. J. Stress and obesity. Annu. Rev. Psychol. 70, 703\u2013718 (2019).","journal-title":"Annu. Rev. Psychol."},{"key":"2499_CR351","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41574-019-0298-z","volume":"16","author":"H Herzog","year":"2020","unstructured":"Herzog, H. Integrated pathways that control stress and energy homeostasis. Nat. Rev. Endocrinol. 16, 75\u201376 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2499_CR352","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cmet.2019.04.001","volume":"30","author":"CK Ip","year":"2019","unstructured":"Ip, C. K. et al. Amygdala NPY circuits promote the development of accelerated obesity under chronic stress conditions. Cell Metab. 30, 111\u2013128.e6 (2019).","journal-title":"Cell Metab."},{"key":"2499_CR353","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1172\/JCI57660","volume":"121","author":"J-C Chuang","year":"2011","unstructured":"Chuang, J.-C. et al. Ghrelin mediates stress-induced food-reward behavior in mice. J. Clin. Invest. 121, 2684\u20132692 (2011).","journal-title":"J. Clin. Invest."},{"key":"2499_CR354","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106259","volume":"26","author":"NJ Queen","year":"2023","unstructured":"Queen, N. J. et al. Social isolation exacerbates diet-induced obesity and peripheral inflammation in young male mice under thermoneutrality. iScience 26, 106259 (2023).","journal-title":"iScience"},{"key":"2499_CR355","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1037\/a0020760","volume":"29","author":"MA Whisman","year":"2010","unstructured":"Whisman, M. A. Loneliness and the metabolic syndrome in a population-based sample of middle-aged and older adults. Health Psychol. 29, 550\u2013554 (2010).","journal-title":"Health Psychol."},{"key":"2499_CR356","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1530\/ERC-16-0359","volume":"23","author":"A Sumis","year":"2016","unstructured":"Sumis, A. et al. Social isolation induces autophagy in the mouse mammary gland: link to increased mammary cancer risk. Endocr. Relat. Cancer 23, 839\u2013856 (2016).","journal-title":"Endocr. Relat. Cancer"},{"key":"2499_CR357","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fphys.2017.00665","volume":"8","author":"D Guarino","year":"2017","unstructured":"Guarino, D., Nannipieri, M., Iervasi, G., Taddei, S. & Bruno, R. M. The role of the autonomic nervous system in the pathophysiology of obesity. Front. Physiol. 8, 665 (2017).","journal-title":"Front. Physiol."},{"key":"2499_CR358","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/HYPERTENSIONAHA.119.12885","volume":"74","author":"G Grassi","year":"2019","unstructured":"Grassi, G. et al. Sympathetic neural overdrive in the obese and overweight state. Hypertension 74, 349\u2013358 (2019).","journal-title":"Hypertension"},{"key":"2499_CR359","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70271","volume":"11","author":"M Francois","year":"2022","unstructured":"Francois, M., Canal Delgado, I., Shargorodsky, N., Leu, C. S. & Zeltser, L. Assessing the effects of stress on feeding behaviors in laboratory mice. Elife 11, e70271 (2022).","journal-title":"Elife"},{"key":"2499_CR360","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/01.HYP.0000242642.42177.49","volume":"48","author":"M Esler","year":"2006","unstructured":"Esler, M. et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48, 787\u2013796 (2006).","journal-title":"Hypertension"},{"key":"2499_CR361","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/hr.2011.173","volume":"35","author":"GZ Kalil","year":"2012","unstructured":"Kalil, G. Z. & Haynes, W. G. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens. Res. 35, 4\u201316 (2012).","journal-title":"Hypertens. Res."},{"key":"2499_CR362","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1113\/jphysiol.2011.221036","volume":"590","author":"MM Smith","year":"2012","unstructured":"Smith, M. M. & Minson, C. T. Obesity and adipokines: effects on sympathetic overactivity. J. Physiol. 590, 1787\u20131801 (2012).","journal-title":"J. Physiol."},{"key":"2499_CR363","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cmet.2024.09.012","volume":"37","author":"K Sakamoto","year":"2024","unstructured":"Sakamoto, K. et al. Overnutrition causes insulin resistance and metabolic disorder through increased sympathetic nervous system activity. Cell Metab. 37, 121\u2013137.e6 (2024).","journal-title":"Cell Metab."},{"key":"2499_CR364","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/1940-6207.CAPR-08-0238","volume":"2","author":"JB Williams","year":"2009","unstructured":"Williams, J. B. et al. A model of gene\u2012environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev. Res. (Philos.) 2, 850\u2013861 (2009).","journal-title":"Cancer Prev. Res. (Philos.)"},{"key":"2499_CR365","doi-asserted-by":"publisher","first-page":"925687","DOI":"10.3389\/fonc.2022.925687","volume":"12","author":"S Mehra","year":"2022","unstructured":"Mehra, S., Singh, S. & Nagathihalli, N. Emerging role of CREB in epithelial to mesenchymal plasticity of pancreatic cancer. Front. Oncol. 12, 925687 (2022).","journal-title":"Front. Oncol."},{"key":"2499_CR366","first-page":"309","volume":"25","author":"C Wu","year":"2023","unstructured":"Wu, C. et al. Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Nat. Cell Biol. 25, 309\u2013322 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR367","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1053\/j.gastro.2022.02.017","volume":"162","author":"X Shi","year":"2022","unstructured":"Shi, X. et al. Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2-AKT-TGF-\u03b2 signaling axis in pancreatic cancer. Gastroenterology 162, 2004\u20132017.e2 (2022).","journal-title":"Gastroenterology"},{"key":"2499_CR368","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2025.101606","volume":"19","author":"S Srinivasan","year":"2025","unstructured":"Srinivasan, S. et al. CREB drives acinar to ductal cells reprogramming and promotes pancreatic cancer progression in preclinical models of alcoholic pancreatitis. Cell Mol. Gastroenterol. Hepatol. 19, 101606 (2025).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2499_CR369","doi-asserted-by":"publisher","first-page":"1408949","DOI":"10.3389\/fnmol.2024.1408949","volume":"17","author":"MAR Chowdhury","year":"2024","unstructured":"Chowdhury, M. A. R., Haq, M. M., Lee, J. H. & Jeong, S. Multi-faceted regulation of CREB family transcription factors. Front. Mol. Neurosci. 17, 1408949 (2024).","journal-title":"Front. Mol. Neurosci."},{"key":"2499_CR370","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1073\/pnas.0501076102","volume":"102","author":"X Zhang","year":"2005","unstructured":"Zhang, X. et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl Acad. Sci. USA 102, 4459\u20134464 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR371","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1021\/cr500452k","volume":"115","author":"BM Dancy","year":"2015","unstructured":"Dancy, B. M. & Cole, P. A. Protein lysine acetylation by p300\/CBP. Chem. Rev. 115, 2419\u20132452 (2015).","journal-title":"Chem. Rev."},{"key":"2499_CR372","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s00018-020-03525-8","volume":"77","author":"A Steven","year":"2020","unstructured":"Steven, A. et al. What turns CREB on? And off? And why does it matter?. Cell Mol. Life Sci. 77, 4049\u20134067 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"2499_CR373","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1002\/mc.23086","volume":"58","author":"J Cui","year":"2019","unstructured":"Cui, J. et al. Activating transcription factor 1 promoted migration and invasion in lung cancer cells through regulating EGFR and MMP-2. Mol. Carcinog. 58, 1919\u20131924 (2019).","journal-title":"Mol. Carcinog."},{"key":"2499_CR374","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ajhg.2019.05.004","volume":"105","author":"J Tian","year":"2019","unstructured":"Tian, J. et al. Systematic functional interrogation of genes in GWAS loci Identified ATF1 as a key driver in colorectal cancer modulated by a promoter-enhancer interaction. Am. J. Hum. Genet. 105, 29\u201347 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"2499_CR375","first-page":"600","volume":"123","author":"K Yamada","year":"2013","unstructured":"Yamada, K. et al. EWS\/ATF1 expression induces sarcomas from neural crest-derived cells in mice. J. Clin. Invest. 123, 600\u2013610 (2013).","journal-title":"J. Clin. Invest."},{"key":"2499_CR376","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0092-8674(83)90157-5","volume":"34","author":"E Rozengurt","year":"1983","unstructured":"Rozengurt, E., Stroobant, P., Waterfield, M. D., Deuel, T. F. & Keehan, M. Platelet-derived growth factor elicits cyclic AMP accumulation in Swiss 3T3 cells: role of prostaglandin production. Cell 34, 265\u2013272 (1983).","journal-title":"Cell"},{"key":"2499_CR377","doi-asserted-by":"publisher","first-page":"46868","DOI":"10.1074\/jbc.M406858200","volume":"279","author":"F Ribeiro-Neto","year":"2004","unstructured":"Ribeiro-Neto, F. et al. cAMP-dependent oncogenic action of Rap1b in the thyroid gland. J. Biol. Chem. 279, 46868\u201346875 (2004).","journal-title":"J. Biol. Chem."},{"key":"2499_CR378","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41556-018-0122-3","volume":"20","author":"KC Patra","year":"2018","unstructured":"Patra, K. C. et al. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat. Cell Biol. 20, 811\u2013822 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR379","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbapap.2013.03.007","volume":"1834","author":"SS Taylor","year":"2013","unstructured":"Taylor, S. S., Zhang, P., Steichen, J. M., Keshwani, M. M. & Kornev, A. P. PKA: lessons learned after twenty years. Biochim. Biophys. Acta 1834, 1271\u20131278 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"2499_CR380","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nrm1527","volume":"5","author":"W Wong","year":"2004","unstructured":"Wong, W. & Scott, J. D. AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell Biol. 5, 959\u2013970 (2004).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2499_CR381","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.tips.2017.11.006","volume":"39","author":"N Musheshe","year":"2018","unstructured":"Musheshe, N., Schmidt, M. & Zaccolo, M. cAMP: from long-range second messenger to nanodomain signalling. Trends Pharm. Sci. 39, 209\u2013222 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"2499_CR382","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/pharmrev.120.000086","volume":"73","author":"M Zaccolo","year":"2021","unstructured":"Zaccolo, M., Zerio, A. & Lobo, M. J. Subcellular organization of the cAMP signaling pathway. Pharm. Rev. 73, 278\u2013309 (2021).","journal-title":"Pharm. Rev."},{"key":"2499_CR383","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2174\/1570159X21666230803101629","volume":"22","author":"G Kyriatzis","year":"2023","unstructured":"Kyriatzis, G., Khrestchatisky, M., Ferhat, L. & Chatzaki, E. A. Neurotensin and neurotensin receptors in stress-related disorders: pathophysiology & novel drug targets. Curr. Neuropharmacol. 22, 916\u2013934 (2023).","journal-title":"Curr. Neuropharmacol."},{"key":"2499_CR384","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41586-022-05575-3","volume":"613","author":"JL Johnson","year":"2023","unstructured":"Johnson, J. L. et al. An atlas of substrate specificities for the human serine\/threonine kinome. Nature 613, 759\u2013766 (2023).","journal-title":"Nature"},{"key":"2499_CR385","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1152\/physiol.00037.2010","volume":"26","author":"E Rozengurt","year":"2011","unstructured":"Rozengurt, E. Protein kinase D signaling: multiple biological functions in health and disease. Physiology 26, 23\u201333 (2011).","journal-title":"Physiology"},{"key":"2499_CR386","doi-asserted-by":"publisher","first-page":"13205","DOI":"10.1074\/jbc.R500002200","volume":"280","author":"E Rozengurt","year":"2005","unstructured":"Rozengurt, E., Rey, O. & Waldron, R. T. Protein kinase D signaling. J. Biol. Chem. 280, 13205\u201313208 (2005).","journal-title":"J. Biol. Chem."},{"key":"2499_CR387","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7200","volume":"6","author":"G-Y Liou","year":"2015","unstructured":"Liou, G.-Y. et al. Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia. Nat. Commun. 6, 6200 (2015).","journal-title":"Nat. Commun."},{"key":"2499_CR388","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-09-1145","volume":"9","author":"KB Harikumar","year":"2010","unstructured":"Harikumar, K. B. et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol. Cancer Ther. 9, 1136\u20131146 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR389","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.molmet.2013.09.002","volume":"2","author":"RW Schwenk","year":"2013","unstructured":"Schwenk, R. W., Vogel, H. & Sch\u00fcrmann, A. Genetic and epigenetic control of metabolic health. Mol. Metab. 2, 337\u2013347 (2013).","journal-title":"Mol. Metab."},{"key":"2499_CR390","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2008.11.018","volume":"136","author":"G Sumara","year":"2009","unstructured":"Sumara, G. et al. Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. Cell 136, 235\u2013248 (2009).","journal-title":"Cell"},{"key":"2499_CR391","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13145","volume":"22","author":"MC Renton","year":"2021","unstructured":"Renton, M. C., McGee, S. L. & Howlett, K. F. The role of protein kinase D (PKD) in intracellular nutrient sensing and regulation of adaptive responses to the obese environment. Obes. Rev. 22, e13145 (2021).","journal-title":"Obes. Rev."},{"key":"2499_CR392","doi-asserted-by":"publisher","first-page":"119814","DOI":"10.1016\/j.bbamcr.2024.119814","volume":"1871","author":"MC Renton","year":"2024","unstructured":"Renton, M. C., McGee, S. L. & Howlett, K. F. The role of protein kinase D (PKD) in obesity: lessons from the heart and other tissues. Biochim. Biophys. Acta Mol. Cell Res. 1871, 119814 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"2499_CR393","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.17219\/acem\/151026","volume":"31","author":"N Zhang","year":"2022","unstructured":"Zhang, N., Shi, L. & Wang, Y. CREB-associated glycosylation and function in human disease. Adv. Clin. Exp. Med. 31, 1289\u20131297 (2022).","journal-title":"Adv. Clin. Exp. Med."},{"key":"2499_CR394","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02224-z","volume":"21","author":"T Zheng","year":"2021","unstructured":"Zheng, T. et al. Systematical analysis reveals a strong cancer relevance of CREB1-regulated genes. Cancer Cell Int. 21, 530 (2021).","journal-title":"Cancer Cell Int."},{"key":"2499_CR395","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1158\/1078-0432.CCR-11-2953","volume":"18","author":"HM Mohan","year":"2012","unstructured":"Mohan, H. M. et al. Molecular pathways: the role of NR4A orphan nuclear receptors in cancer. Clin. Cancer Res. 18, 3223\u20133228 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR396","doi-asserted-by":"publisher","first-page":"972984","DOI":"10.3389\/fonc.2022.972984","volume":"12","author":"S Deng","year":"2022","unstructured":"Deng, S., Chen, B., Huo, J. & Liu, X. Therapeutic potential of NR4A1 in cancer: focus on metabolism. Front. Oncol. 12, 972984 (2022).","journal-title":"Front. Oncol."},{"key":"2499_CR397","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.1073\/pnas.1007088107","volume":"107","author":"N Volakakis","year":"2010","unstructured":"Volakakis, N. et al. NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc. Natl Acad. Sci. USA 107, 12317\u201312322 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR398","doi-asserted-by":"publisher","first-page":"6824","DOI":"10.1158\/0008-5472.CAN-10-1992","volume":"70","author":"SO Lee","year":"2010","unstructured":"Lee, S. O. et al. Inactivation of the orphan nuclear receptor TR3\/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res. 70, 6824\u20136836 (2010).","journal-title":"Cancer Res."},{"key":"2499_CR399","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1523\/JNEUROSCI.0367-19.2019","volume":"40","author":"EE Esvald","year":"2020","unstructured":"Esvald, E. E. et al. CREB family transcription factors are major mediators of BDNF transcriptional autoregulation in cortical neurons. J. Neurosci. 40, 1405\u20131426 (2020).","journal-title":"J. Neurosci."},{"key":"2499_CR400","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1523\/JNEUROSCI.1341-22.2023","volume":"43","author":"J Catal\u00e0-Solsona","year":"2023","unstructured":"Catal\u00e0-Solsona, J. et al. Activity-dependent Nr4a2 induction modulates synaptic expression of AMPA receptors and plasticity via a Ca(2+\/)CRTC1\/CREB pathway. J. Neurosci. 43, 3028\u20133041 (2023).","journal-title":"J. Neurosci."},{"key":"2499_CR401","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1523\/JNEUROSCI.2672-10.2011","volume":"31","author":"S-J Zhang","year":"2011","unstructured":"Zhang, S.-J. et al. A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage. J. Neurosci. 31, 4978\u20134990 (2011).","journal-title":"J. Neurosci."},{"key":"2499_CR402","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1038\/s41388-021-01771-z","volume":"40","author":"N Azizi","year":"2021","unstructured":"Azizi, N. et al. Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. Oncogene 40, 3118\u20133135 (2021).","journal-title":"Oncogene"},{"key":"2499_CR403","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.554502","volume":"11","author":"JH Zhu","year":"2020","unstructured":"Zhu, J. H. et al. The key genes for perineural invasion in pancreatic ductal adenocarcinoma identified with monte-carlo feature selection method. Front. Genet. 11, 554502 (2020).","journal-title":"Front. Genet."},{"key":"2499_CR404","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s13402-023-00907-5","volume":"47","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. ATF3-induced activation of NF-\u03baB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Cell Oncol. (Dordr.) 47, 939\u2013950 (2024).","journal-title":"Cell Oncol. (Dordr.)"},{"key":"2499_CR405","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109706","volume":"36","author":"X Li","year":"2021","unstructured":"Li, X. et al. ATF3 promotes the serine synthesis pathway and tumor growth under dietary serine restriction. Cell Rep. 36, 109706 (2021).","journal-title":"Cell Rep."},{"key":"2499_CR406","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma, S., Meng, Z., Chen, R. & Guan, K.-L. The Hippo Pathway: biology and pathophysiology. Annu. Rev. Biochem. 88, 577\u2013604 (2019).","journal-title":"Annu. Rev. Biochem."},{"key":"2499_CR407","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/hep.26420","volume":"58","author":"J Wang","year":"2013","unstructured":"Wang, J. et al. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology 58, 1011\u20131020 (2013).","journal-title":"Hepatology"},{"key":"2499_CR408","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1161\/ATVBAHA.118.312212","volume":"39","author":"Q Yu","year":"2019","unstructured":"Yu, Q. et al. PI3K\u03b3 (Phosphoinositide 3-Kinase \u03b3) regulates vascular smooth muscle cell phenotypic modulation and neointimal formation through CREB (Cyclic AMP-response element binding protein)\/YAP (Yes-associated protein) signaling. Arterioscler. Thromb. Vasc. Biol. 39, e91\u2013e105 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2499_CR409","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12672-023-00626-1","volume":"14","author":"W Fang","year":"2023","unstructured":"Fang, W. et al. Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via the cAMP-CREB axis. Discov. Oncol. 14, 17 (2023).","journal-title":"Discov. Oncol."},{"key":"2499_CR410","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00852-0","volume":"20","author":"S Yin","year":"2022","unstructured":"Yin, S. et al. Receptor activity-modifying protein 1 regulates mouse skin fibroblast proliferation via the G\u03b1i3-PKA-CREB-YAP axis. Cell Commun. Signal. 20, 52 (2022).","journal-title":"Cell Commun. Signal."},{"key":"2499_CR411","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/jcmm.13324","volume":"22","author":"L Chen","year":"2018","unstructured":"Chen, L. et al. cAMP response element-binding protein and Yes-associated protein form a feedback loop that promotes neurite outgrowth. J. Cell Mol. Med. 22, 374\u2013381 (2018).","journal-title":"J. Cell Mol. Med."},{"key":"2499_CR412","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41420-024-01936-1","volume":"10","author":"N Liu","year":"2024","unstructured":"Liu, N. et al. FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer. Cell Death Discov. 10, 172 (2024).","journal-title":"Cell Death Discov."},{"key":"2499_CR413","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori, K. J. et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 9, 205\u2013217 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2499_CR414","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"2499_CR415","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527\u2013540 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2499_CR416","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1053\/j.gastro.2024.05.032","volume":"167","author":"A Boil\u00e8ve","year":"2024","unstructured":"Boil\u00e8ve, A. et al. Organoids for functional precision medicine in advanced pancreatic cancer. Gastroenterology 167, 961\u2013976.e913 (2024).","journal-title":"Gastroenterology"},{"key":"2499_CR417","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00280-015-2730-y","volume":"75","author":"S Kordes","year":"2015","unstructured":"Kordes, S. et al. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother. Pharm. 75, 1135\u20131141 (2015).","journal-title":"Cancer Chemother. Pharm."},{"key":"2499_CR418","doi-asserted-by":"publisher","first-page":"175883592412849","DOI":"10.1177\/17588359241284911","volume":"16","author":"AJ Ouissam","year":"2024","unstructured":"Ouissam, A. J., Hind, C., Sami Aziz, B. & Said, A. Inhibition of the PI3K\/AKT\/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. Ther. Adv. Med. Oncol. 16, 17588359241284911 (2024).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2499_CR419","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","volume":"21","author":"PL Bedard","year":"2015","unstructured":"Bedard, P. L. et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin. Cancer Res. 21, 730\u2013738 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR420","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/cts.12802","volume":"13","author":"AG Murphy","year":"2020","unstructured":"Murphy, A. G. et al. A phase I study of dinaciclib in combination with MK-2206 in patients with advanced pancreatic cancer. Clin. Transl. Sci. 13, 1178\u20131188 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"2499_CR421","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","volume":"142","author":"R Roskoski","year":"2019","unstructured":"Roskoski, R. Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers. Pharm. Res 142, 151\u2013168 (2019).","journal-title":"Pharm. Res"},{"key":"2499_CR422","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/oncolo\/oyac237","volume":"28","author":"PM Grierson","year":"2023","unstructured":"Grierson, P. M. et al. Phase Ib study of ulixertinib plus gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic adenocarcinoma. Oncologist 28, e115\u2013e123 (2023).","journal-title":"Oncologist"},{"key":"2499_CR423","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/ijms25031631","volume":"25","author":"C Adamopoulos","year":"2024","unstructured":"Adamopoulos, C., Cave, D. D. & Papavassiliou, A. G. Inhibition of the RAF\/MEK\/ERK signaling cascade in pancreatic cancer: recent advances and future perspectives. Int. J. Mol. Sci. 25, 1631 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2499_CR424","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdu482","volume":"26","author":"AW Tolcher","year":"2015","unstructured":"Tolcher, A. W. et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann. Oncol. 26, 58\u201364 (2015).","journal-title":"Ann. Oncol."},{"key":"2499_CR425","doi-asserted-by":"publisher","first-page":"S484","DOI":"10.1016\/j.annonc.2020.08.675","volume":"31","author":"P LoRusso","year":"2020","unstructured":"LoRusso, P. et al. 561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic\/advanced solid tumours. Ann. Oncol. 31, S484 (2020).","journal-title":"Ann. Oncol."},{"key":"2499_CR426","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/SLA.0000000000006610","volume":"281","author":"L Huang","year":"2025","unstructured":"Huang, L. et al. Development and validation of the predictive and prognostic chemoresist signature in resected pancreatic ductal adenocarcinoma: multicohort study. Ann. Surg. 281, 632\u2013644 (2025).","journal-title":"Ann. Surg."},{"key":"2499_CR427","doi-asserted-by":"publisher","first-page":"103749","DOI":"10.1016\/j.critrevonc.2022.103749","volume":"176","author":"M Mortazavi","year":"2022","unstructured":"Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E. & Firuzi, O. Prospects of targeting PI3K\/AKT\/mTOR pathway in pancreatic cancer. Crit. Rev. Oncol. Hematol. 176, 103749 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2499_CR428","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nsmb.1564","volume":"16","author":"F Catalanotti","year":"2009","unstructured":"Catalanotti, F. et al. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat. Struct. Mol. Biol. 16, 294\u2013303 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2499_CR429","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1128\/MCB.00569-09","volume":"30","author":"DA Ritt","year":"2010","unstructured":"Ritt, D. A., Monson, D. M., Specht, S. I. & Morrison, D. K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell Biol. 30, 806\u2013819 (2010).","journal-title":"Mol. Cell Biol."},{"key":"2499_CR430","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/msb.2011.27","volume":"7","author":"R Fritsche-Guenther","year":"2011","unstructured":"Fritsche-Guenther, R. et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol. Syst. Biol. 7, 489 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"2499_CR431","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/j.cellsig.2008.08.006","volume":"20","author":"X Li","year":"2008","unstructured":"Li, X., Huang, Y., Jiang, J. & Frank, S. J. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal. 20, 2145\u20132155 (2008).","journal-title":"Cell Signal."},{"key":"2499_CR432","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","volume":"13","author":"E Rozengurt","year":"2014","unstructured":"Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of Feedback Loops Mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477\u20132488 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR433","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1158\/1535-7163.MCT-14-0669","volume":"14","author":"HP Soares","year":"2015","unstructured":"Soares, H. P. et al. Dual PI3K\/mTOR inhibitors induce rapid overactivation of the MEK\/ERK pathway in human pancreatic cancer cells through suppression of mTORC2. Mol. Cancer Ther. 14, 1014\u20131023 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR434","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","volume":"108","author":"JT Garrett","year":"2011","unstructured":"Garrett, J. T. et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl Acad. Sci. USA 108, 5021\u20135026 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR435","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58\u201371 (2011).","journal-title":"Cancer Cell"},{"key":"2499_CR436","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann, T., Sers, C., Der, C. J. & Papke, B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer 11, 91\u2013116 (2025).","journal-title":"Trends Cancer"},{"key":"2499_CR437","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41575-024-00951-y","volume":"21","author":"SD Haldar","year":"2024","unstructured":"Haldar, S. D. & Azad, N. S. Unlocking the promise of RAS inhibition in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 535\u2013536 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2499_CR438","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2499_CR439","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2499_CR440","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"2499_CR441","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"2499_CR442","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"2499_CR443","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","volume":"30","author":"D Wei","year":"2024","unstructured":"Wei, D., Wang, L., Zuo, X., Maitra, A. & Bresalier, R. S. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin. Cancer Res. 30, 655\u2013662 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2499_CR444","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2135\u20132161 (2024).","journal-title":"Cancer Discov."},{"key":"2499_CR445","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay, K. C. M. et al. Dual Inhibition of KRASG12D and Pan-ERBB Is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 83, 3001\u20133012 (2023).","journal-title":"Cancer Res."},{"key":"2499_CR446","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14, 994\u20131017 (2024).","journal-title":"Cancer Discov."},{"key":"2499_CR447","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","volume":"68","author":"J Cregg","year":"2025","unstructured":"Cregg, J. et al. Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers. J. Med. Chem. 68, 6064\u20136083 (2025).","journal-title":"J. Med. Chem."},{"key":"2499_CR448","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"2499_CR449","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919\u2013926 (2024).","journal-title":"Nature"},{"key":"2499_CR450","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1158\/2159-8290.CD-24-1475","volume":"15","author":"M Orlen","year":"2025","unstructured":"Orlen, M. et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma. Cancer Discov. 15, 1697\u20131716 (2025).","journal-title":"Cancer Discov."},{"key":"2499_CR451","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.drudis.2024.104250","volume":"30","author":"P Filis","year":"2025","unstructured":"Filis, P., Salgkamis, D., Matikas, A. & Zerdes, I. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236. Drug Discov. Today 30, 104250 (2025).","journal-title":"Drug Discov. Today"},{"key":"2499_CR452","doi-asserted-by":"publisher","first-page":"12287","DOI":"10.1021\/acs.jmedchem.5c01441","volume":"68","author":"Z Ma","year":"2025","unstructured":"Ma, Z., Zhou, M., Shen, Q. & Zhou, J. RAS(ON) Therapies on the horizon to address KRAS Resistance: highlight on a phase III clinical candidate daraxonrasib (RMC-6236). J. Med. Chem. 68, 12287\u201312292 (2025).","journal-title":"J. Med. Chem."},{"key":"2499_CR453","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","volume":"24","author":"N Perurena","year":"2024","unstructured":"Perurena, N., Situ, L. & Cichowski, K. Combinatorial strategies to target RAS-driven cancers. Nat. Rev. Cancer 24, 316\u2013337 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2499_CR454","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/0008-5472.CAN-23-2504","volume":"84","author":"V Kumarasamy","year":"2024","unstructured":"Kumarasamy, V. et al. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 84, 1115\u20131132 (2024).","journal-title":"Cancer Res."},{"key":"2499_CR455","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","volume":"48","author":"AV Pobbati","year":"2023","unstructured":"Pobbati, A. V., Kumar, R., Rubin, B. P. & Hong, W. Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem. Sci. 48, 450\u2013462 (2023).","journal-title":"Trends Biochem. Sci."},{"key":"2499_CR456","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-23-0538","volume":"23","author":"CJ Moure","year":"2024","unstructured":"Moure, C. J. et al. Activation of Hepatocyte Growth Factor\/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1\/TEAD Small Molecule Inhibitor. Mol. Cancer Ther. 23, 1095\u20131108 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"2499_CR457","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1038\/s44319-024-00217-3","volume":"25","author":"A Kulkarni","year":"2024","unstructured":"Kulkarni, A. et al. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. EMBO Rep. 25, 3944\u20133969 (2024).","journal-title":"EMBO Rep."},{"key":"2499_CR458","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","volume":"4","author":"TJ Hagenbeek","year":"2023","unstructured":"Hagenbeek, T. J. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat. Cancer 4, 812\u2013828 (2023).","journal-title":"Nat. Cancer"},{"key":"2499_CR459","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau, E. A. et al. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat. Cancer 5, 1102\u20131120 (2024).","journal-title":"Nat. Cancer"},{"key":"2499_CR460","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56634-y","volume":"16","author":"S Paul","year":"2025","unstructured":"Paul, S. et al. Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition. Nat. Commun. 16, 1743 (2025).","journal-title":"Nat. Commun."},{"key":"2499_CR461","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman, N. A., Burchard, P. R., Dunne, R. F. & Linehan, D. C. Immunologic strategies in pancreatic cancer: making cold tumors hot. J. Clin. Oncol. 40, 2789\u20132805 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2499_CR462","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).","journal-title":"Nat. Commun."},{"key":"2499_CR463","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00706","volume":"7","author":"T Coston","year":"2023","unstructured":"Coston, T. et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: mayo clinic experience. JCO Precis. Oncol. 7, e2200706 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"2499_CR464","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"2499_CR465","first-page":"62","volume":"4","author":"P Gulhati","year":"2023","unstructured":"Gulhati, P. et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat. Cancer 4, 62\u201380 (2023).","journal-title":"Nat. Cancer"},{"key":"2499_CR466","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"2499_CR467","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"2499_CR468","doi-asserted-by":"publisher","first-page":"1321176","DOI":"10.3389\/fnins.2023.1321176","volume":"17","author":"Y Lei","year":"2023","unstructured":"Lei, Y. et al. Investigating the crosstalk between chronic stress and immune cells: implications for enhanced cancer therapy. Front. Neurosci. 17, 1321176 (2023).","journal-title":"Front. Neurosci."},{"key":"2499_CR469","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S1470-2045(21)00596-9","volume":"23","author":"DD Shi","year":"2022","unstructured":"Shi, D. D. et al. Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncol. 23, e62\u2013e74 (2022).","journal-title":"Lancet Oncol."},{"key":"2499_CR470","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/apc-19-45","volume":"3","author":"AB Blair","year":"2020","unstructured":"Blair, A. B. et al. Nonselective \u03b2-adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival. Ann. Pancreat. Cancer 3, 8 (2020).","journal-title":"Ann. Pancreat. Cancer"},{"key":"2499_CR471","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/COC.0000000000000359","volume":"41","author":"MS Beg","year":"2018","unstructured":"Beg, M. S. et al. Impact of concurrent medication use on pancreatic cancer survival\u2014SEER-medicare analysis. Am. J. Clin. Oncol. 41, 766\u2013771 (2018).","journal-title":"Am. J. Clin. Oncol."},{"key":"2499_CR472","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/0284186X.2021.1953136","volume":"60","author":"NC St\u00f8er","year":"2021","unstructured":"St\u00f8er, N. C. et al. Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. Acta Oncol. 60, 1146\u20131153 (2021).","journal-title":"Acta Oncol."},{"key":"2499_CR473","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","volume":"10","author":"I Pernicova","year":"2014","unstructured":"Pernicova, I. & Korbonits, M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10, 143\u2013156 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2499_CR474","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bcp.2018.01.049","volume":"153","author":"S Olivier","year":"2018","unstructured":"Olivier, S., Foretz, M. & Viollet, B. Promise and challenges for direct small molecule AMPK activators. Biochem. Pharm. 153, 147\u2013158 (2018).","journal-title":"Biochem. Pharm."},{"key":"2499_CR475","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.abe7565","volume":"373","author":"Y Yan","year":"2021","unstructured":"Yan, Y. et al. Structure of an AMPK complex in an inactive, ATP-bound state. Science 373, 413\u2013419 (2021).","journal-title":"Science"},{"key":"2499_CR476","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cmet.2017.10.009","volume":"27","author":"SC Lin","year":"2018","unstructured":"Lin, S. C. & Hardie, D. G. AMPK: sensing glucose as well as cellular energy status. Cell Metab. 27, 299\u2013313 (2018).","journal-title":"Cell Metab."},{"key":"2499_CR477","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41422-019-0163-6","volume":"29","author":"Y Zong","year":"2019","unstructured":"Zong, Y. et al. Hierarchical activation of compartmentalized pools of AMPK depends on severity of nutrient or energy stress. Cell Res. 29, 460\u2013473 (2019).","journal-title":"Cell Res."},{"key":"2499_CR478","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.bbrc.2012.11.010","volume":"430","author":"J Sinnett-Smith","year":"2013","unstructured":"Sinnett-Smith, J., Kisfalvi, K., Kui, R. & Rozengurt, E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem. Biophys. Res. Commun. 430, 352\u20133527 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2499_CR479","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.celrep.2014.09.036","volume":"9","author":"M DeRan","year":"2014","unstructured":"DeRan, M. et al. Energy stress regulates Hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 9, 495\u2013503 (2014).","journal-title":"Cell Rep."},{"key":"2499_CR480","doi-asserted-by":"publisher","first-page":"G763","DOI":"10.1152\/ajpgi.00170.2019","volume":"317","author":"TS Dong","year":"2019","unstructured":"Dong, T. S. et al. Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G763\u2013g772 (2019).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2499_CR481","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/jnci\/djae021","volume":"116","author":"L O\u2019Connor","year":"2024","unstructured":"O\u2019Connor, L. et al. Association of metformin use and cancer incidence: a systematic review and meta-analysis. J. Natl. Cancer Inst. 116, 518\u2013529 (2024).","journal-title":"J. Natl. Cancer Inst."},{"key":"2499_CR482","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.2015.63.3511","volume":"34","author":"R Chaiteerakij","year":"2016","unstructured":"Chaiteerakij, R. et al. Metformin use and survival of patients with pancreatic cancer: a cautionary lesson. J. Clin. Oncol. 34, 1898\u20131904 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2499_CR483","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/jnci\/djae070","volume":"116","author":"CWF van Eijck","year":"2024","unstructured":"van Eijck, C. W. F., Vadgama, D., van Eijck, C. H. J. & Wilmink, J. W. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. J. Natl. Cancer Inst. 116, 1374\u20131383 (2024).","journal-title":"J. Natl. Cancer Inst."},{"key":"2499_CR484","doi-asserted-by":"publisher","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner, R., Murad, H., Agay, N., Olmer, L. & Freedman, L. S. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw. Open 7, e2350408 (2024).","journal-title":"JAMA Netw. Open"},{"key":"2499_CR485","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang, L., Xu, R., Kaelber, D. C. & Berger, N. A. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw. Open 7, e2421305 (2024).","journal-title":"JAMA Netw. Open"},{"key":"2499_CR486","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","volume":"117","author":"L Wang","year":"2025","unstructured":"Wang, L., Wang, Q., Li, L., Kaelber, D. C. & Xu, R. GLP-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. J. Natl. Cancer Inst. 117, 476\u2013485 (2025).","journal-title":"J. Natl. Cancer Inst."},{"key":"2499_CR487","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jdi.14229","volume":"15","author":"Y Du","year":"2024","unstructured":"Du, Y. et al. A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data. J. Diab. Investig. 15, 1422\u20131433 (2024).","journal-title":"J. Diab. Investig."},{"key":"2499_CR488","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","volume":"76","author":"OF Kuzu","year":"2016","unstructured":"Kuzu, O. F., Noory, M. A. & Robertson, G. P. The role of cholesterol in cancer. Cancer Res 76, 2063\u20132070 (2016).","journal-title":"Cancer Res"},{"key":"2499_CR489","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","volume":"16","author":"G Sorrentino","year":"2014","unstructured":"Sorrentino, G. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 16, 357\u2013366 (2014).","journal-title":"Nat. Cell Biol."},{"key":"2499_CR490","first-page":"E89","volume":"111","author":"Z Wang","year":"2014","unstructured":"Wang, Z. et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl Acad. Sci. USA 111, E89\u2013E98 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2499_CR491","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.gastha.2022.04.012","volume":"1","author":"S Ako","year":"2022","unstructured":"Ako, S. et al. Statins inhibit inflammatory cytokine production by macrophages and acinar-to-ductal metaplasia of pancreatic cells. Gastro Hep Adv. 1, 640\u2013651 (2022).","journal-title":"Gastro Hep Adv."},{"key":"2499_CR492","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/cncr.29256","volume":"121","author":"EJ Walker","year":"2015","unstructured":"Walker, E. J., Ko, A. H., Holly, E. A. & Bracci, P. M. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer 121, 1287\u20131294 (2015).","journal-title":"Cancer"},{"key":"2499_CR493","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ijc.29813","volume":"138","author":"M-J Chen","year":"2016","unstructured":"Chen, M.-J. et al. Statins and the risk of pancreatic cancer in Type 2 diabetic patients\u2014a population-based cohort study. Int. J. Cancer 138, 594\u2013603 (2016).","journal-title":"Int. J. Cancer"},{"key":"2499_CR494","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.cgh.2018.02.022","volume":"16","author":"T Hamada","year":"2018","unstructured":"Hamada, T. et al. Prediagnosis use of statins associates with increased survival times of patients with pancreatic cancer. Clin. Gastroenterol. Hepatol. 16, 1300\u20131306.e3 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2499_CR495","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MPA.0000000000001226","volume":"48","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Statin use and risk of pancreatic cancer: an updated meta-analysis of 26 studies. Pancreas 48, 142\u2013150 (2019).","journal-title":"Pancreas"},{"key":"2499_CR496","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/1940-6207.CAPR-21-0123","volume":"14","author":"K Saito","year":"2021","unstructured":"Saito, K. et al. Statin exposure and pancreatic cancer incidence: a Japanese regional population-based cohort study, the Shizuoka Study. Cancer Prev. Res. 14, 863\u2013872 (2021).","journal-title":"Cancer Prev. Res."},{"key":"2499_CR497","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48441-8","volume":"15","author":"JH Park","year":"2024","unstructured":"Park, J. H. et al. Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression. Nat. Commun. 15, 4099 (2024).","journal-title":"Nat. Commun."},{"key":"2499_CR498","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1097\/MPA.0000000000002411","volume":"54","author":"K Saito","year":"2025","unstructured":"Saito, K. et al. Impact of statin use on survival in patients with unresectable pancreatic cancer receiving gemcitabine plus nab-paclitaxel: a multicenter retrospective study. Pancreas 54, e107\u2013e113 (2025).","journal-title":"Pancreas"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02499-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T18:05:35Z","timestamp":1767463535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02499-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":498,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02499-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}